<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS158911</article-id><article-id pub-id-type="doi">10.1101/2022.12.16.520808</article-id><article-id pub-id-type="archive">PPR586117</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Lung extracellular matrix modulates KRT5<sup>+</sup> basal cell activity in pulmonary fibrosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hewitt</surname><given-names>Richard J.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Puttur</surname><given-names>Franz</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gaboriau</surname><given-names>David C. A.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Fercoq</surname><given-names>Frédéric</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Fresquet</surname><given-names>Maryline</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Traves</surname><given-names>William J.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yates</surname><given-names>Laura L.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Walker</surname><given-names>Simone A.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Molyneaux</surname><given-names>Philip L.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kemp</surname><given-names>Samuel V.</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Nicholson</surname><given-names>Andrew G.</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rice</surname><given-names>Alexandra</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lennon</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Carlin</surname><given-names>Leo M.</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Byrne</surname><given-names>Adam J.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Maher</surname><given-names>Toby M.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><name><surname>Lloyd</surname><given-names>Clare M.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>National Heart and Lung Institute, Imperial College London, SW7 2AZ, UK</aff><aff id="A2"><label>2</label>Royal Brompton and Harefield Hospitals, Guy’s and St Thomas’ NHS Foundation Trust, London, SW3 6NP, UK</aff><aff id="A3"><label>3</label>Facility for Imaging by Light Microscopy, National Heart and Lung Institute, Imperial College London, SW7 2AZ, UK</aff><aff id="A4"><label>4</label>Cancer Research UK Beatson Institute, Glasgow, G61 1BD, UK</aff><aff id="A5"><label>5</label>Wellcome Centre for Cell-Matrix Research, Division of Cell-Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, M13 9PT, UK</aff><aff id="A6"><label>6</label>Current address: Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, City Campus, Hucknall Road, Nottingham, NG5 1PB, UK</aff><aff id="A7"><label>7</label>School of Cancer Sciences, University of Glasgow, Glasgow, G61 1QH, UK</aff><aff id="A8"><label>8</label>Current address: Keck Medicine of USC, 1510 San Pablo Street, Los Angeles, California, 90033, USA</aff><author-notes><corresp id="CR1">
<label>*</label><bold>Corresponding author:</bold> Professor Clare Lloyd, National Heart and Lung Institute, Imperial College London, London, SW7 2AZ, UK. <email>c.lloyd@imperial.ac.uk</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>23</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="preprint"><day>18</day><month>12</month><year>2022</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Aberrant expansion of KRT5<sup>+</sup> basal cells in the distal lung accompanies progressive alveolar epithelial cell loss and tissue remodelling during fibrogenesis in idiopathic pulmonary fibrosis (IPF). The mechanisms determining activity of KRT5<sup>+</sup> cells in IPF have not been delineated. Here, we reveal a potential mechanism by which KRT5<sup>+</sup> cells migrate within the fibrotic lung, navigating regional differences in collagen topography. <italic>In vitro</italic>, KRT5<sup>+</sup> cell migratory characteristics and expression of remodelling genes are modulated by extracellular matrix (ECM) composition and organisation. Mass spectrometry-based proteomics revealed compositional differences in ECM components secreted by primary human lung fibroblasts (HLF) from IPF patients compared to controls. Over-expression of ECM glycoprotein, Secreted Protein Acidic and Cysteine Rich (SPARC) in the IPF HLF matrix restricts KRT5<sup>+</sup> cell migration <italic>in vitro</italic>. Together, our findings demonstrate how changes to the ECM in IPF directly influence KRT5<sup>+</sup> cell behaviour and function contributing to remodelling events in the fibrotic niche.</p></abstract><kwd-group><kwd>Pulmonary fibrosis</kwd><kwd>basal cell</kwd><kwd>extracellular matrix</kwd><kwd>cell migration</kwd></kwd-group></article-meta></front><body><p id="P2">Single-cell RNA-sequencing has provided unique insight into the cellular complexity of the lung in idiopathic pulmonary fibrosis (IPF); a progressive and incurable scarring lung disease<sup><xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R3">3</xref></sup>. It has revealed novel cell phenotypes associated with dramatic changes to the lung microenvironment which are characteristic of this disease<sup><xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref></sup>. In IPF, normal alveoli are obliterated by a dense fibrous matrix causing architectural remodelling and the formation of distorted, cystic airspaces termed honeycomb cysts (HCs)<sup><xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R5">5</xref></sup>. In fibrotic lung, basal cells (BCs) expressing cytokeratin 5 (KRT5) – which normally reside in the conducting airways<sup><xref ref-type="bibr" rid="R6">6</xref></sup> - extend into the alveolar space and line HCs<sup><xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R7">7</xref>–<xref ref-type="bibr" rid="R9">9</xref></sup>. The presence of KRT5 BCs in the alveolar compartment in IPF has been associated with increased mortality<sup><xref ref-type="bibr" rid="R10">10</xref></sup>. Studies have focused on delineating the origin of KRT5<sup>+</sup> BCs in IPF<sup><xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R12">12</xref></sup> but little is known about how these cells interact with the lung extracellular matrix (ECM) to contribute to disease pathology.</p><p id="P3">ECM provides a physical scaffold for the adhesion of resident cells and hosts a complex array of biochemical and mechanical signals that influence cell phenotype and behaviour<sup><xref ref-type="bibr" rid="R13">13</xref></sup>. Composed of around 1000 structural and regulatory proteins, the human matrisome<sup><xref ref-type="bibr" rid="R14">14</xref></sup> is highly dynamic and undergoes remodelling<sup><xref ref-type="bibr" rid="R15">15</xref></sup>. Within the lung, ECM is produced and secreted by fibroblasts, of which there are multiple subpopulations with distinct anatomical localisation<sup><xref ref-type="bibr" rid="R16">16</xref></sup>. ECM dysregulation in disease states, compromises the activity of many different cells and processes, disturbing tissue homeostasis with a profound effect on organ function<sup><xref ref-type="bibr" rid="R15">15</xref></sup>. ECM alterations during IPF have been shown to directly influence fibroblast activity through mechanosignaling pathways, catalysing the pathobiology of the disease<sup><xref ref-type="bibr" rid="R17">17</xref>–<xref ref-type="bibr" rid="R19">19</xref></sup>.</p><p id="P4">Epithelial cells acquire an enhanced migratory phenotype during tissue development, repair, cancer and fibrosis<sup><xref ref-type="bibr" rid="R20">20</xref></sup>. Cell migration is a key aspect of immune cell function within lung tissue and previous work from our laboratory has shown it is highly dependent on cues from the ECM<sup><xref ref-type="bibr" rid="R21">21</xref></sup>. ECM properties including molecular composition and topology likely influence cell motility<sup><xref ref-type="bibr" rid="R22">22</xref></sup>. Understanding mechanisms of epithelial cell redistribution during fibrotic lung remodelling is critical in the development of therapeutics that may help to preserve adequate gas exchange.</p><p id="P5">Herein we utilise human lung tissue, primary cells and cell-derived matrices to show how changes in the properties of the ECM during fibrotic remodelling dictate KRT5<sup>+</sup> BC distribution and migration. We reveal for the first time that the local tissue microenvironment of the fibrotic lung drives a transcriptional and functional change in KRT5<sup>+</sup> BCs. These findings provide insight into pulmonary epithelial cell– ECM interactions that are likely relevant to other tissues in health and disease states.</p><sec id="S1" sec-type="results"><title>Results</title><sec id="S2"><title>Distinct regional ECM organisation in the fibrotic lung influences KRT5<sup>+</sup> basal cell distribution</title><p id="P6">KRT5<sup>+</sup> BCs normally line the basement membrane of the healthy human airway but have also been observed in distal lung parenchyma and HC regions in IPF<sup><xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R7">7</xref></sup>. We confirmed this in lung tissue sections from IPF patients, and normal lung tissue sections from control patients (<xref ref-type="fig" rid="F8">Extended data Fig. 1</xref>). To determine ECM organisation in regions of distal lung populated by KRT5<sup>+</sup> BCs, we examined IPF and control lung tissue sections by second harmonic generation (SHG), 2- photon microscopy (<xref ref-type="fig" rid="F1">Fig. 1a</xref>, <xref ref-type="table" rid="T1">Extended data Table 1</xref>). SHG is a label-free, nonlinear microscopy technique that facilitates study of collagen organisation without the need for extensive tissue processing that may disrupt ECM architecture<sup><xref ref-type="bibr" rid="R23">23</xref>, <xref ref-type="bibr" rid="R24">24</xref></sup>. This approach relies on the unique property of non-centrosymmetric structures such as fibrillar collagens including type I and III collagen – relevant to IPF - to emit a SHG signal<sup><xref ref-type="bibr" rid="R23">23</xref></sup>. Equivalent regions of IPF and control lung were compared, with the addition of fibrotic and HC regions that were present exclusively in IPF sections (<xref ref-type="fig" rid="F1">Fig. 1b</xref> and <xref ref-type="fig" rid="F8">Extended data Fig. 1i</xref>). In IPF lung tissue, loss of normal alveolar architecture and marked fibrotic remodelling was accompanied by the accumulation of KRT5<sup>+</sup> BCs distributed as clusters, individual cells or lining HCs (<xref ref-type="fig" rid="F1">Fig. 1b</xref>).</p><p id="P7">As expected KRT5<sup>+</sup> BCs were highly abundant in peribronchial areas of IPF and control lungs, compared with alveolar and perivascular regions (<xref ref-type="fig" rid="F1">Fig. 1c</xref>). However, in IPF, an abnormal expansion of KRT5<sup>+</sup> BC numbers in fibrotic and HC regions were observed that were absent from equivalent alveolar regions in control lungs (<xref ref-type="fig" rid="F1">Fig. 1c</xref>).</p><p id="P8">SHG texture analysis using a grey level cooccurrence matrix (GLCM) has been employed to study collagen organisation in conducting airways of patients with asthma<sup><xref ref-type="bibr" rid="R25">25</xref></sup>. In our study, quantitative analysis of SHG images for collagen density, fibre orientation and image texture (using GLCM) demonstrated significant inter-regional differences in collagen organisation (<xref ref-type="fig" rid="F1">Fig. 1d-g</xref>). Principal component analysis (PCA) of quantitative image analysis data (<xref ref-type="table" rid="T2">Extended Table 2</xref>) showed clustering of regions based on collagen characteristics (<xref ref-type="fig" rid="F1">Fig. 1d</xref> and <xref ref-type="fig" rid="F9">Extended data Fig. 2a, b</xref>). Higher collagen density was evident throughout the IPF lung (<xref ref-type="fig" rid="F1">Fig. 1e</xref>). IPF HC regions clustered with the peribronchial regions of IPF and controls due to increased collagen density (<xref ref-type="fig" rid="F1">Fig. 1e</xref>) and coherency of fibre orientation (<xref ref-type="fig" rid="F1">Fig. 1f</xref>) within these areas. PCA clustering of fibrotic and perivascular regions of IPF and controls was driven by increased entropy; a measure of the degree of randomness in the image (<xref ref-type="fig" rid="F1">Fig. 1g</xref>). Compared to IPF HC regions, collagen in fibrotic regions demonstrated lower inverse difference moment (IDM) and angular second moment (ASM) corresponding respectively, to lower homogeneity and lower uniformity in the images (<xref ref-type="fig" rid="F9">Extended data Fig. 2c, d</xref>). This indicates that excess collagen deposited in fibrotic regions is more disorganised than in HC regions, creating differences in matrix topography within the IPF lung. Collagen organisation in IPF HC regions was comparable to that surrounding healthy airways.</p><p id="P9">Differences in regional collagen organisation determined by SHG were correlated with KRT5<sup>+</sup> BC number and arrangement. We found a significant positive correlation between KRT5<sup>+</sup> BC frequency and collagen density (<xref ref-type="fig" rid="F1">Fig. 1h</xref>), and fibre coherency (<xref ref-type="fig" rid="F1">Fig. 1i</xref>).</p><p id="P10">Next, we used high-dimensional imaging mass cytometry (IMC) to explore ECM composition in regions of distal lung tissue adjacent to KRT5<sup>+</sup> BCs (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Lung tissue sections were investigated for collagens I, III, IV and versican; ECM components previously identified to be enriched in fibroblastic foci<sup><xref ref-type="bibr" rid="R26">26</xref></sup>. In normal lung (<xref ref-type="fig" rid="F2">Fig. 2a</xref>) collagen I and III – both fibrillar collagens - co-localised around airways (<xref ref-type="fig" rid="F2">Fig. 2a</xref>) and blood vessels (<xref ref-type="fig" rid="F10">Extended data Fig. 3</xref>). Collagen IV - a network-forming collagen – was located at the basement membrane region of airways and alveoli (<xref ref-type="fig" rid="F2">Fig. 2a</xref>) and around blood vessels (<xref ref-type="fig" rid="F10">Extended data Fig. 3</xref>). Versican - a large proteoglycan - could be visualised superficially in the airway epithelium, in interstitial areas and immune cells within the alveoli (<xref ref-type="fig" rid="F2">Fig. 2</xref> and <xref ref-type="fig" rid="F10">Extended data Fig. 3</xref>). In lung tissue from patients with IPF, collagen I, III, and IV were abundantly present adjacent to KRT5<sup>+</sup> BCs in the peribronchial, fibrotic interstitium and HC regions (<xref ref-type="fig" rid="F2">Fig. 2b – d</xref>). Versican was more abundant in the fibrotic interstitial areas and superficially within the KRT5<sup>+</sup> epithelium in HC.</p><p id="P11">High-resolution microscopy of damaged alveolar regions of IPF lung showed KRT5<sup>+</sup> BCs adjacent to alpha-SMA<sup>+</sup> cells embedded within collagen matrix (<xref ref-type="fig" rid="F11">Extended data Fig. 4a, b</xref>) raising the possibility of direct epithelial-stromal interactions in this niche. Crosstalk between AT2 cells and fibroblasts are important in maintaining the alveolar niche<sup><xref ref-type="bibr" rid="R27">27</xref></sup>, however, KRT5<sup>+</sup> BC – fibroblast interactions in the distal lung have not been previously described. Signalling between these neighbouring cells may drive pathology in the IPF lung.</p></sec><sec id="S3"><title>KRT5<sup>+</sup> basal cell migration is directly modulated by ECM proteins</title><p id="P12">Mechanisms governing KRT5<sup>+</sup> BC redistribution in the fibrotic lung have not been elucidated. Structural cues in the pulmonary microenvironment are critical in determining cell migration kinetics<sup><xref ref-type="bibr" rid="R21">21</xref>, <xref ref-type="bibr" rid="R28">28</xref></sup>. Given the relationship between KRT5<sup>+</sup> BC numbers and SHG collagen characteristics, we tested the effect of different ECM constituents on KRT5<sup>+</sup> BC migration. Human KRT5<sup>+</sup> BCs were isolated from airway brushings and expanded in culture. Flow cytometry and immunofluorescence microscopy was used to validate expression of the characteristic BC markers KRT5 and p63 (<xref ref-type="fig" rid="F3">Fig. 3a</xref> and <xref ref-type="fig" rid="F12">Extended data Fig. 5</xref>), and typical BC morphology was demonstrated with Airyscan (<xref ref-type="fig" rid="F3">Fig. 3b</xref>). We confirmed the capacity of these KRT5<sup>+</sup> BCs to undergo normal mucociliary differentiation in an air-liquid interface (ALI) model (<xref ref-type="fig" rid="F3">Fig. 3c</xref>). KRT5<sup>+</sup> BCs from healthy controls and IPF patients were then cultured on ECM proteins; collagen I, III, IV and versican (<xref ref-type="fig" rid="F3">Fig. 3d</xref>). These were selected because of their close spatial association with KRT5<sup>+</sup> BCs in the distal lung as confirmed by IMC (<xref ref-type="fig" rid="F2">Fig. 2</xref>). We used time-lapse microscopy and semi-automated tracking to analyse cell migration over 12 hours. KRT5<sup>+</sup> BCs from healthy donors (n=1593 cells) and IPF patients (n=1574 cells) were tracked on the ECM ligands. The pattern of KRT5<sup>+</sup> BC migration varied according to ECM ligand (<xref ref-type="fig" rid="F3">Fig. 3e</xref>, <xref ref-type="supplementary-material" rid="SD1">Extended data Video 1</xref>). A mesenchymal- like mode of migration was observed with exploratory lamellipodia protruding at the leading edge of cells<sup><xref ref-type="bibr" rid="R22">22</xref></sup>. BC speed and displacement were enhanced on collagen I and III, compared to collagen IV and versican (<xref ref-type="fig" rid="F3">Fig. 3f, g</xref>). Indices of directional persistence – straightness (or directionality ratio) (<xref ref-type="fig" rid="F3">Fig. 3h</xref>) and mean squared displacement (MSD) (<xref ref-type="fig" rid="F3">Fig. 3i</xref>) were also increased on collagen I and III. KRT5<sup>+</sup> BCs were spatially restricted and oscillated in a fixed position on basement membrane components, collagen IV and versican (<xref ref-type="fig" rid="F3">Fig. 3e</xref>). These results show that individual ECM ligands have a profound influence on KRT5<sup>+</sup> BC migratory dynamics.</p></sec><sec id="S4"><title>Interaction with a 3D cell-derived matrix induces gene expression changes in migratory KRT5<sup>+</sup> basal cells</title><p id="P13">In our 2D culture system, significant migratory differences were driven by changes in ECM ligand but not by disease-associated KRT5<sup>+</sup> BC-intrinsic differences. Cell-derived matrix (CDM), generated by fibroblasts cultured at high density, can recapitulate the complex 3D microenvironment of tissue in simplified, <italic>in vitro</italic> models<sup><xref ref-type="bibr" rid="R29">29</xref></sup>. CDMs have been employed to study important biological questions, such as how normal ECM regulates cancer cell proliferation<sup><xref ref-type="bibr" rid="R30">30</xref></sup>but not in IPF. To investigate the effect of lung ECM on KRT5<sup>+</sup> BC function, we established a system using human lung fibroblasts (HLFs) from IPF lung tissue to generate CDMs and then studied KRT5<sup>+</sup> BC migratory characteristics (<xref ref-type="fig" rid="F4">Fig. 4a</xref>). Cultured at high-density for 21 days, IPF HLFs efficiently synthesised ECM to generate a 3D matrix (<xref ref-type="fig" rid="F4">Fig. 4bi</xref>). Decellularization was performed and preservation of CDM structural integrity confirmed by immunofluorescence microscopy for ECM constituents (<xref ref-type="fig" rid="F4">Fig. 4bii, biii</xref>). KRT5<sup>+</sup> BCs from healthy controls (n=213 cells) and IPF patients (n=362 cells) were fluorescently labelled and tracked on the fibrotic CDMs over 12 hours using high resolution time-lapse microscopy (<xref ref-type="supplementary-material" rid="SD1">Extended data Video 2</xref>). Broadly, two migratory patterns were observed that differed from migratory patterns observed in the 2D culture system. A subset of BCs adopted an elongated morphology with lamellipodia, migrating in a linear, directed manner according to matrix topography (<xref ref-type="supplementary-material" rid="SD1">Extended data Supplementary Video 3 and 4</xref>). 20-30% of KRT5<sup>+</sup> BCs were spatially restricted with a displacement distance of less than 20μm and displayed an oscillatory behaviour projecting filopodia to explore the local matrix microenvironment. There were no significant differences in cell speed, displacement or track straightness between healthy and IPF KRT5<sup>+</sup> BCs (<xref ref-type="fig" rid="F4">Fig. 4c-f</xref>) on IPF CDMs. Cell tracks plotted from centroid showed overlap between healthy and IPF KRT5<sup>+</sup> BCs(<xref ref-type="fig" rid="F4">Fig. 4g</xref>). This demonstrates KRT5<sup>+</sup> BCs can migrate through a 3D fibrotic matrix and this is not influenced by cell-intrinsic disease status.</p><p id="P14">Next, we investigated how changes in ECM influence expression of genes associated with inflammation, cell migration and tissue remodelling, in KRT5<sup>+</sup> BCs. A PCR array was performed using KRT5<sup>+</sup> BCs from healthy controls and IPF patients cultured on collagen I (2D model) or IPF CDMs (3D model) (<xref ref-type="fig" rid="F4">Fig. 4h</xref>). Discrete clustering of samples was determined by ECM microenvironment rather than KRT5<sup>+</sup> BC disease status (<xref ref-type="fig" rid="F4">Fig. 4i,j</xref>). Direct comparison of gene expression changes between healthy and IPF KRT5<sup>+</sup> BCs on either ligand revealed very few differences (<xref ref-type="fig" rid="F13">Extended data Fig. 6</xref>). Conversely, significant gene expression changes were found in KRT5+ BCs cultured on collagen I compared to IPF CDM (<xref ref-type="fig" rid="F4">Fig. 4k</xref>). Collagen 1 alpha 2 chain (<italic>COL1A2</italic>) and serpin family E family member 1 (<italic>SERPINE1</italic>) genes were upregulated in healthy and IPF KRT5<sup>+</sup> BCs cultured on IPF CDM. Exclusively upregulated in IPF KRT5<sup>+</sup> cells were collagen genes (<italic>COL3A1</italic>, <italic>COL1A1</italic>), and MMP9, a matrix metalloproteinase. When compared to IPF CDM, KRT5<sup>+</sup> BCs cultured on collagen I over-expressed genes encoding growth factors (<italic>CTGF</italic>, <italic>HBEGF</italic>), pro-inflammatory chemokines (<italic>CXCL1</italic>, <italic>CXCL2</italic>) and integrin subunits such as <italic>ITGA3</italic>. Taken together, these data indicate that the ECM microenvironment plays a critical role in determining gene expression changes in pathways relevant to tissue remodelling and fibrosis.</p></sec><sec id="S5"><title>IPF fibroblast-derived matrix restrains KRT5<sup>+</sup> basal cell migration</title><p id="P15">To investigate whether disease-specific changes in lung ECM microenvironment differentially regulate cell migration, healthy KRT5<sup>+</sup> BCs were tracked through control CDMs (n=301 cells) compared to IPF CDMs (n=257 cells) (<xref ref-type="fig" rid="F5">Fig. 5a</xref>). Direct interactions between KRT5<sup>+</sup> BCs and fibronectin fibres were demonstrated by high-resolution immunofluorescence microscopy (<xref ref-type="fig" rid="F5">Fig. 5b</xref>). No significant differences were found when comparing KRT5<sup>+</sup> BC track speed, straightness or displacement through control versus IPF CDMs in a nested analysis (<xref ref-type="fig" rid="F5">Fig. 5c – 5e</xref>). However, visualisation of all tracks plotted from centroid showed greater spatial restriction of KRT5<sup>+</sup> BCs through IPF CDMs compared to control CDMs (<xref ref-type="fig" rid="F5">Fig. 5f</xref>). KRT5+ BC tracks were shorter and more random through IPF CDMs than through control CDMs (<xref ref-type="fig" rid="F5">Fig. 5g</xref>). Excluding non-migratory cells with displacement &lt; 20μm, we studied cell track frequency distribution by displacement showing fewer KRT5<sup>+</sup> BCs were able to move further than 100 μm through IPF CDMs compared to controls (<xref ref-type="fig" rid="F5">Fig. 5h</xref>). Mean square displacement over time was reduced through the IPF CDMs compared to control CDMs (<xref ref-type="fig" rid="F5">Fig. 5i</xref>). These findings suggest that IPF HLFs produce a matrix microenvironment that is more restrictive to KRT5<sup>+</sup> BC migration.</p></sec><sec id="S6"><title>IPF fibroblast-derived matrix has a distinct matrisome</title><p id="P16">We postulated that differences in KRT5<sup>+</sup> BC migration observed on disease compared to control matrix could be driven by compositional changes in the matrisome<sup><xref ref-type="bibr" rid="R31">31</xref></sup>. Previous studies have used mass spectrometry-based proteomics to characterise proteins extracted from IPF and control lung tissue resections<sup><xref ref-type="bibr" rid="R32">32</xref>–<xref ref-type="bibr" rid="R34">34</xref></sup>. In contrast, we explored the components in CDMs generated directly by IPF and control HLFs to directly identify proteins in the matrices that KRT5<sup>+</sup> BCs had interacted with. Fibroblast-deposited ECM from IPF patients and non-fibrotic controls were isolated and enriched using a fractionation protocol established by Lennon et al.<sup><xref ref-type="bibr" rid="R35">35</xref></sup> (<xref ref-type="fig" rid="F6">Fig. 6a</xref>). 2795 proteins were identified by mass spectrometry. When cross-referenced with the human matrisome database<sup><xref ref-type="bibr" rid="R36">36</xref></sup>,154 matrix proteins were identified. Functional enrichment analysis using the Database for Annotation, Visualisation and Integrated Discovery (DAVID)<sup><xref ref-type="bibr" rid="R37">37</xref></sup> revealed that the top 10 GO Biological Processes included extracellular matrix organisation, cell adhesion, response to wounding and regulation of cell migration (<xref ref-type="fig" rid="F6">Fig. 6b</xref>). The most abundant proteins in the CDMs were ECM glycoproteins and regulators (<xref ref-type="fig" rid="F6">Fig. 6c</xref>). PCA (<xref ref-type="fig" rid="F6">Fig. 6d</xref>) and unsupervised hierarchical clustering of matrisome proteins by normalised abundance (<xref ref-type="fig" rid="F6">Fig. 6e</xref>), demonstrated distinct clustering of IPF HLF derived CDMs compared to controls.</p><p id="P17">We observed 19 matrix proteins that were significantly differentially expressed between IPF and control CDMs, and of these, 14 were upregulated in IPF CDMs compared to controls (<xref ref-type="fig" rid="F6">Fig. 6f</xref>). Insulin Like Growth Factor Binding Protein 5 (IGFBP-5) was the most significantly upregulated protein in IPF CDMs compared to controls (2.61 Log2fc, p &lt;0.001) and is linked to cell migration<sup><xref ref-type="bibr" rid="R38">38</xref></sup>. Other significantly upregulated proteins with known roles in the regulation of cell migration and ECM organisation, included Growth Arrest Specific Protein-6 (GAS6), Fibronectin (FN1) and Secreted Protein Acidic and Cysteine Rich (SPARC) (<xref ref-type="fig" rid="F6">Fig. 6g</xref>). Lysyl oxidase (LOX) and lysyl oxidase like 2 (LOXL2) - involved in collagen cross-linking - were over-expressed in the IPF CDMs compared to controls. Serpin family F member 1 (SERPINF1) and fibrilin-1 (FBN1) – both upregulated in lung tissue from IPF patients compared to control<sup><xref ref-type="bibr" rid="R33">33</xref></sup> – were also significantly upregulated in the IPF CDMs compared to control. Analysis using the STRING database showed specific protein-protein interactions between IGFBP-5, GAS6, FN1, SPARC, Milk Fat Globule-EGF Factor 8 (MFGE8) and Fibrillin-1 (FBN1) (FDR stringency: 1%) (<xref ref-type="fig" rid="F6">Fig. 6h</xref>). This analysis identifies distinct differences in the matrisome of IPF CDMs compared to controls, with many of the upregulated proteins in IPF likely to play a role in ECM organisation and cell migration.</p></sec><sec id="S7"><title>SPARC protein modulates KRT5<sup>+</sup> basal cell migration in vitro</title><p id="P18">We next sought to functionally validate the influence of mass spectrometry-identified proteins on KRT5<sup>+</sup> BC migration. The migratory dynamics of healthy KRT5<sup>+</sup> BCs was evaluated using time-lapse imaging with recombinant IGFBP-5, GAS6, FN1 or SPARC in a 2D culture environment. KRT5<sup>+</sup> BCs do not migrate on uncoated culture plates therefore plates were pre-coated with collagen I to promote adherence and migration prior to addition of the selected ligand. It was evident that recombinant IGFBP5, GAS6 and FN1 did not appreciably alter KRT5<sup>+</sup> BC migration on collagen I (<xref ref-type="fig" rid="F14">Extended data Fig. 7</xref>). The multifunctional ECM glycoprotein SPARC has been shown to localise to the IPF fibroblast foci by immunohistochemistry<sup><xref ref-type="bibr" rid="R39">39</xref></sup>. SPARC did not significantly change cell track speed (<xref ref-type="fig" rid="F7">Fig. 7a</xref>) but did cause a significant reduction in straightness ratio and cell displacement in healthy KRT5<sup>+</sup> BCs (<xref ref-type="fig" rid="F7">Fig. 7b and 7c</xref>). Together these results indicate that an abundance of SPARC in IPF CDMs compared to controls, restricts KRT5<sup>+</sup> BC movement. This could be visualised at a single-track level (<xref ref-type="fig" rid="F7">Fig. 7d</xref>), from centroid (<xref ref-type="fig" rid="F7">Fig. 7e</xref>) and by mean squared displacement (<xref ref-type="fig" rid="F7">Fig. 7f</xref>). For the first time, we identify SPARC as a unique regulator of KRT5<sup>+</sup> BC migration (<xref ref-type="fig" rid="F7">Fig. 7g</xref>) and its deposition by IPF HLFs represents a mechanism that could explain the retention of KRT5<sup>+</sup> BCs in the fibrotic niche.</p></sec></sec><sec id="S8" sec-type="discussion"><title>Discussion</title><p id="P19">KRT5<sup>+</sup> BCs re-populate the remodelled, fibrotic lung in advanced IPF<sup><xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R12">12</xref></sup>, but the pathological mechanisms underlying this process have not been defined. This study provides unique insight into the interaction between KRT5<sup>+</sup> BCs and the ECM microenvironment of the IPF distal lung. We show that KRT5<sup>+</sup> BC migratory behaviour is modulated by ECM structure and composition. In IPF CDM compared to control CDM, KRT5<sup>+</sup> BC movement becomes restricted. Moreover, we detected a greater abundance of the glycoprotein, SPARC in IPF CDMs and show that this molecule restricts movement of KRT5+ BCs. We postulate that through this mechanism, KRT5<sup>+</sup> BCs are retained in fibrotic lung tissue, where they likely contribute to tissue remodelling, disease pathology and ultimately organ dysfunction.</p><p id="P20">ECM maintains tissue architecture and the biomechanical properties necessary for optimal organ function<sup><xref ref-type="bibr" rid="R31">31</xref></sup>. It provides signals to neighbouring cells, influencing cell phenotype and behaviour<sup><xref ref-type="bibr" rid="R40">40</xref></sup>, and profibrotic processes in IPF<sup><xref ref-type="bibr" rid="R41">41</xref></sup>. While previous SHG studies<sup><xref ref-type="bibr" rid="R42">42</xref>–<xref ref-type="bibr" rid="R44">44</xref></sup> have summarised collagen organisation in whole lung from patients with IPF, they have failed to take into account the heterogenous nature of fibrotic lung tissue. We analysed regional collagen organisation and KRT5<sup>+</sup> BC distribution in IPF distal lung. We demonstrate dense and tangled collagen fibres in fibrotic regions of the lung – akin to those found in perivascular regions – were associated with fewer KRT5<sup>+</sup> BCs arranged as single cells or clusters. Contrary to this collagen surrounding IPF HCs was more organised, mirroring that seen in healthy peribronchial regions, and KRT5<sup>+</sup> BC arrangement was comparable to that found in the normal airway. Intriguingly, scRNA-seq has identified collagen-producing subpopulations residing in different anatomical locations in control and fibrotic lungs<sup><xref ref-type="bibr" rid="R16">16</xref></sup>. Future work is required to elucidate whether these subpopulations govern differential collagen organisation in pulmonary fibrosis.</p><p id="P21">Following lung injury in mice, distal airway progenitor cells migrate to repopulate damaged alveolar regions of the lung<sup><xref ref-type="bibr" rid="R12">12</xref></sup>. The complex biophysical properties of ECM including composition, topography, and stiffness determine 3D cell migration<sup><xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R45">45</xref></sup>. We have shown KRT5<sup>+</sup> BCs possess the capacity to migrate <italic>in vitro</italic>, and this is modulated by ECM components. Previous studies of airway epithelial cell migration mainly focus on collective migration of epithelial cell sheets during wound healing<sup><xref ref-type="bibr" rid="R46">46</xref>–<xref ref-type="bibr" rid="R49">49</xref></sup>. In this study we sought to understand the migratory dynamics of individual KRT5<sup>+</sup> BCs within fibrotic areas remote to the airway. In the lung, the majority of interstitial collagen is secreted and organised into sheets and cables by fibroblasts<sup><xref ref-type="bibr" rid="R50">50</xref></sup>. We generated CDM from HLFs to recapitulate ECM architecture and composition of native tissue<sup><xref ref-type="bibr" rid="R29">29</xref>, <xref ref-type="bibr" rid="R51">51</xref></sup>. Cell-matrix adhesions are important in modulating migration<sup><xref ref-type="bibr" rid="R52">52</xref>, <xref ref-type="bibr" rid="R53">53</xref></sup>, and local microenvironmental variations in fibre stiffness in a 3D matrix altered focal adhesion dynamics and fibroblast motility<sup><xref ref-type="bibr" rid="R54">54</xref></sup>. It is likely that regional differences in matrix geometry within CDMs from the same donor were responsible for heterogeneity in the KRT5<sup>+</sup> BC migratory patterns observed.</p><p id="P22">CDMs generated from IPF fibroblasts displayed a distinct matrisome and restricted KRT5<sup>+</sup> BC migration compared to control CDMs. Many of the proteins detected in IPF CDMs have also been identified in proteomic studies of IPF whole lung tissue<sup><xref ref-type="bibr" rid="R32">32</xref>–<xref ref-type="bibr" rid="R34">34</xref>, <xref ref-type="bibr" rid="R55">55</xref></sup>, and have been implicated in disease pathogenesis including, IGFBP-5<sup><xref ref-type="bibr" rid="R56">56</xref></sup>, GDF-15<sup><xref ref-type="bibr" rid="R57">57</xref></sup>, WNT5B<sup><xref ref-type="bibr" rid="R58">58</xref></sup>, LOXL2<sup><xref ref-type="bibr" rid="R43">43</xref></sup>, GAS6<sup><xref ref-type="bibr" rid="R59">59</xref></sup>, FN<sup><xref ref-type="bibr" rid="R26">26</xref></sup> and SPARC<sup><xref ref-type="bibr" rid="R60">60</xref>, <xref ref-type="bibr" rid="R61">61</xref></sup>. IPF CDMs therefore represent a disease-relevant model with which to study epithelial cell – matrix interactions. SPARC is a matricellular protein secreted at significantly higher levels in conditioned media from IPF fibroblasts compared to normal lung fibroblasts<sup><xref ref-type="bibr" rid="R61">61</xref>, <xref ref-type="bibr" rid="R62">62</xref></sup>. In addition to disrupting epithelial integrity, increased SPARC promoted AT2 cell migration in a wound healing assay<sup><xref ref-type="bibr" rid="R61">61</xref></sup>. This effect on AT2 cell migration differs to that which we observed with KRT5<sup>+</sup> BCs, however this may relate to differences in migration assay and cell type studied. SPARC regulates an array of biological activities<sup><xref ref-type="bibr" rid="R63">63</xref></sup>, and can bind fibrillar collagens and modulate collagen fibril assembly<sup><xref ref-type="bibr" rid="R64">64</xref></sup>. Our data are the first to show a function for SPARC in human tissue. It is feasible that SPARC overexpression in IPF ECM alters collagen assembly, influencing KRT5<sup>+</sup> BC migration capacity.</p><p id="P23">Emerging data suggests there are molecular differences in BC subpopulations in IPF, with expansion of a ‘secretory primed basal’ (SPB) cell subset enriched in HCs in fibrotic lung tissue<sup><xref ref-type="bibr" rid="R65">65</xref></sup>. Airway basal cells from IPF patients have been shown to increase fibroblast proliferation and ECM deposition <italic>in vitro</italic>, and promote fibrotic remodelling in a humanised mouse model<sup><xref ref-type="bibr" rid="R66">66</xref></sup>. We did not find any disease- associated, cell- intrinsic differences in migration. Rather, we show that cues from the ECM microenvironment play a significant role in influencing the activity and mobility of KRT5<sup>+</sup> BCs in the fibrotic niche.</p><p id="P24">Using human primary cells and CDMs, we developed a disease-relevant model to show that the migratory dynamics of BCs are governed by properties of the surrounding matrix. IPF HLFs produce an environment which modifies KRT5<sup>+</sup> BC behaviour. Specifically, SPARC, secreted by IPF fibroblasts restricts movement of KRT5<sup>+</sup> BCs and may play a key role in retaining these cells within fibrotic tissue, where they likely contribute to disease pathology and progression. Our findings have direct relevance to pathological remodelling events in IPF and may be relevant to other biological processes which involve structural cell migration within the lung.</p></sec><sec id="S9" specific-use="web-only"><title>Online Methods</title><sec id="S10"><title>Experimental model and subject details</title><p id="P25">Heathy subjects and IPF patients were prospectively recruited at the Royal Brompton Hospital (London, UK) between March 2017 and March 2020. A diagnosis of IPF was made following multi-disciplinary discussion, according to international guidelines<sup><xref ref-type="bibr" rid="R67">67</xref></sup>. Healthy control subjects included previous and non-smokers with normal lung function (FEV1 &gt;80% predicted for age and height, FEV1/ FVC ratio &gt;70%). All subjects underwent fibreoptic bronchoscopy in accordance with a standard operating procedure<sup><xref ref-type="bibr" rid="R68">68</xref></sup>. Under direct visualisation, two to three bronchial brushings (Olympus) were taken in the right main bronchus and placed directly into Dulbecco’s Modified Eagle Medium (DMEM, Gibco). Ethical approval was granted by the Research Ethics Committee (NRES reference: 15/SC/0101 and 15/LO/1399) and all human material was collected from patients who had provided written informed consent. Fresh lung tissue specimens and archived formalin fixed paraffin embedded (FFPE) lung tissue sections were obtained from the Royal Brompton Hospital (London, UK) with ethical approval (NRES reference: 15/SC/0101 and 15/SC/0569). All specimens were reviewed by a consultant histopathologist. Normal parenchymal lung tissue was obtained during resections for localised lung cancers from sites remote to any tumour mass. IPF tissue samples with evidence of a usual interstitial pneumonia (UIP) histological pattern were procured from explant lung tissue or surgical lung biopsies.</p></sec><sec id="S11"><title>Histology and immunofluorescence microscopy</title><p id="P26">FFPE lung tissue sections (4μm thickness) were deparaffinized by heating at 60°C for 1 hour then immersing three times for 5 minutes in Gentaclear (Genta Medical, UK). A graded alcohol series (100%, 90%, then 70%) followed by phosphate buffer saline (PBS) wash was used to rehydrate the tissue. Antigen retrieval was performed by heating the sections in 0.01M sodium citrate solution (pH 6.0) for 15 minutes at 800 watts in a microwave. To prevent non-specific primary antibody binding the sections were blocked with 10% goat serum (Sigma-Aldrich) for 1 hour (room temperature). The sections were stained overnight at 4°C with primary antibodies to KRT5 (basal cells) and alpha-smooth muscle actin (myofibroblasts). After washing in PBS, secondary antibodies diluted in 10% goat serum were added for 30 minutes at room temperature. The secondary antibody used was goat anti-rabbit IgG conjugated to DyLight® 488 (1:200; Invitrogen). Nuclei were counterstained with DAPI (1:1000; Sigma-Aldrich) or anti-Histone H3 (1:200; C-terminus) AF 594 (#819405; BioLegend) for 20 minutes. ProLong Gold antifade mountant (Life Technologies) was applied directly to the tissue sections. As a negative control, tissue stained only with the secondary antibody was used. The sections were viewed on a Leica SP5 inverted confocal microscope using Leica LAS software. Images were acquired on a Leica SP5 inverted confocal microscope equipped with four lasers (405nm, 488nm, 543nm, 633nm), using a 10x, 20x and 63x oil objective lens, and Leica Application Suite X (LAS X) software. Images were processed in Fiji<sup><xref ref-type="bibr" rid="R69">69</xref></sup>. Regional enumeration of fluorescently labelled KRT5+ cells associated with collagen matrix was performed manually in Fiji (<ext-link ext-link-type="uri" xlink:href="http://fiji.sc">http://fiji.sc</ext-link>).</p></sec><sec id="S12"><title>Mutiplexed imaging</title><p id="P27">Multiplexed imaging of distal lung was adapted from McCowan et al<sup><xref ref-type="bibr" rid="R70">70</xref></sup>. Antigen retrieval was performed on histological sections using Target Retrieval Solution, pH 6.0 (Agilent) (20 min at 97 °C) on a Dako PT retrieval module. Samples were permeabilized and blocked for 20min in PBS/Neutral goat serum (NGS) 10%/BSA1%/TritonX-100 (Tx100) 0.3%/Azide 0.05% at 37 °C and stained with 150μl rabbit anti-Keratin 5 (Polyclonal, Poly19055, BioLegend, 1/200) diluted in PBS/NGS10%/BSA1%/ TX-100 0.3%/Azide 0.05% for 1h. Samples were washed 3 times with PBS/BSA1%/TX-100 0.1%/Azide 0.05% before adding 150 μl of_a solution containing, anti-Histone H3 (1:200; C-terminus) AF 594 (#819405; BioLegend), aSMA-Cy3 (clone 1A4, Sigma, 1/1000) and anti-rabbit-AF647 (polyclonal, A-21244, ThermoFisher) diluted in PBS/ NGS10%/BSA1%/ TX-100 0.3%/Azide 0.05% for 1 hour. Samples were washed 3 times with PBS/BSA1%/TX-100 0.1%/Azide 0.05% and 2 times in PBS. Finally slides were mounted with Vectashield (Vector Laboratories, H-1700).</p></sec><sec id="S13"><title>Second harmonic generation imaging</title><p id="P28">To obtain concurrent second harmonic generation (SHG) images, stained tissue sections were also imaged a Zeiss LSM 880 NLO multiphoton microscope (Beatson Advanced Imaging Resources, Beatson Institute) equipped with a 32 channel Gallium arsenide phosphide (GaAsP) spectral detector (Carl Zeiss) using 20x/1 NA water immersion objective lens. Samples were excited with a tuneable multiphoton laser (680-1300nm) set up at 900nm or 100nm and/or normal lasers (488nm, 561nm and 633nm) depending on immunostaining used, and signal was collected onto a linear array of the 32 GaAsp detectors in lambda mode with a resolution of 8.9nm over the visible spectrum. Spectral images were then unmixed with Zen software (Carl Zeiss) using references spectra acquired from unstained tissues (tissue autofluorescence and Second Harmonic Generation), DAPI-stained tissue or slides labelled with AF488-, Cy3-, AF594- or AF647-conjugated antibodies. Images were acquired in each of the following regions: alveolar (ALV-NORM, ALV-IPF), airway peribronchial (PB-NORM, PB-IPF), perivascular space (PVS-NORM, PVS-IPF), honeycomb cyst (CYST) and fibrotic (FIBRO).</p></sec><sec id="S14"><title>Image texture analysis</title><p id="P29">To analyse the structural characteristics of collagen fibres in each region, a variety of measurements were obtained using Imaris (Oxford Instruments) and OrientationJ<sup><xref ref-type="bibr" rid="R71">71</xref></sup> (<ext-link ext-link-type="uri" xlink:href="http://bigwww.epfl.ch/demo/orientation/">http://bigwww.epfl.ch/demo/orientation/</ext-link>) and GLCM (<ext-link ext-link-type="uri" xlink:href="https://imageJ.nih.gov/ij/plugins/texture.html">https://imageJ.nih.gov/ij/plugins/texture.html</ext-link>) plugins for (Fiji/ ImageJ). Imaris (Oxford Instruments) surface tool was used to segment collagen fibres and tissue autofluorescence to measure collagen intensity and density (defined as % of tissue covered with collagen), and to quantify the number of KRT5+ cells in the different analysed regions. OrientationJ was used to measure fibre coherency utilising properties of the original image, so-called ‘first-order statistics’. Grey-level co-occurrence matrix (GLCM) texture analysis derives statistical measures by considering the spatial relationship of pixels in an image, so-called ‘second-order statistics’. The GLCM features measured included contrast, entropy, correlation, inverse difference moment (IDM) and angular second moment (ASM) (Table S2).</p></sec><sec id="S15"><title>Imaging Mass Cytometry (IMC)</title><sec id="S16"><title>Antibody panel design</title><p id="P30">An antibody panel was designed to capture ECM microenvironment surrounding KRT5<sup>+</sup> BCs in the distal lung. The MaxPar X8 multimetal labelling kit (Standard BioTools Inc.) was used to chelate 100 μg of BSA- and azide- free, purified antibody as per the manufacturer’s protocol; anti- cytokeratin 5 (ab52635) was conjugated with the 164 Dy metal isotope, anti-collagen III (#NB600-594) with the 176 Yb isotope, anti-collagen IV (#NB120-6586) with the 153 Eu isotope, and anti-versican (#ab240200) with the 147 Sm isotope. Each custom - chelated antibody was tested on FFPE tissue sections from controls and patients with IPF to ensure an expected staining pattern and optimal dilution with good signal-to-noise ratio for each channel. The dilution factor was altered for channels with obvious spillover into neighbouring channels.</p></sec><sec id="S17"><title>Imaging</title><p id="P31">FFPE lung tissue sections (4μm thickness) from controls and patients with IPF were stained with H&amp;E and imaged on Aperio Versa Slide Scanner (Leica). Tissue integrity and suitability for IMC was assessed in Aperio ImageScope (Leica). Suitable serial FFPE lung tissue sections were dewaxed by baking in a dry oven at 60°C for 2 hours. The sections were placed in Gentaclear (Genta Medical) for 10 minutes, followed by rehydration in a graded series of ethanol (100%, 95%, 80%, 70%) for 5 minutes each. Sections were washed on a shaker in Maxpar water (Standard BioTools Inc.) for 5 minutes. Heat-induced antigen retrieval was performed at 96°C in Dako Target Retrieval Solution (Agilent; diluted from 10x to 1x). After cooling to less than 70°C, sections were washed with Maxpar water and Maxpar phosphate-buffered saline (PBS; Standard BioTools Inc). The sections were blocked with 3% Bovine serum albumin (BSA; Sigma-Aldrich) in Maxpar PBS (Standard BioTools Inc) for 45 minutes at room temperature (RT). Sections were incubated at 4°C overnight with primary antibodies in 0.5% BSA (Table 2). Slides were washed x2 for 8 minutes in 0.2% Triton X-100 (Sigma-Aldrich) in Maxpar PBS (Standard BioTools Inc), followed by 2 washes in Maxpar PBS (8 minutes per wash). Sections were counterstained with CELL-ID intercalators (Ir; Standard BioTools Inc), added to each section and incubated at RT for 30 minutes. Sections were washed in Maxpar water for 5 minutes and air-dried for 30 minutes. The slides were stored without coverslips at RT until imaging. The Hyperion Imaging System (Standard BioTools Inc) was used to attain IMC images. Following start-up in CyTOF 7.0 (Standard BioTools Inc), the system was calibrated using a 3-element full coverage tuning slide (Standard BioTools Inc) which utilises a polymer matrix containing Yttrium-89, Cerium-140 and Lutetium-175. On completion of successful calibration, simple brightfield images of the tissue were taken using the ‘Panorama’ function, Regions of interest (ROIs) were selected within areas of AR. Laser ablation was performed with laser power 2, frequency 200 Hz and 1μm resolution. Raw data were exported from CyTOF 7.0 in .mcd format. MCD Viewer (Standard BioTools Inc) was used to review each channel to ascertain image quality and pseudo-colours were assigned to channels of interest to generate a composite image which was exported as a .tiff file.</p></sec><sec id="S18"><title>Isolation and culture of primary human bronchial epithelial cells (PBECs)</title><sec id="S19"><title>Submerged culture</title><p id="P32">Freshly collected bronchial brushings were agitated in media to detach cells and centrifuged (300x<italic>g</italic>, 5 minutes). The resultant cell pellet was resuspended in serum-free, Airway Epithelial Growth Medium (PromoCell) containing manufacturer’s supplements and Primocin (InvivoGen), added to protect against microbial contamination. The cell suspension was seeded in a 25cm<sup><xref ref-type="bibr" rid="R2">2</xref></sup> flask (Corning) pre-coated with purified type 1 bovine collagen (PureCol, Advanced BioMatrix). Cells were cultivated at 37°C in a humidified atmosphere of 5% CO<sub>2</sub> and media was refreshed every 48-hours. PBECs were passaged at 80% confluence and cryopreserved in PromoCell media with 10% DMSO (Sigma-Aldrich) and 10% FBS (Gibco) (passage #2). When required, PBECs were thawed quickly in a 37°C water bath and cultured in a pre-coated 75cm<sup><xref ref-type="bibr" rid="R2">2</xref></sup> flask (Corning) until 80% confluent, then passaged for use in experiments (Table S3).</p></sec><sec id="S20"><title>Air-liquid interface culture</title><p id="P33">Passage #3 KRT5+ cells were seeded (4.0 x 10<sup><xref ref-type="bibr" rid="R4">4</xref></sup>/ insert) on purified collagen 1 (Advanced BioMatrix) coated Transwell polyester membrane inserts (6.5mm diameter; 0.4μm pore size; Corning). PneumoCult-Ex media (STEMCELL) containing manufacturer’s supplements, was added to apical and basal chambers and replaced 48-hourly. When confluent, the apical media was removed to promote mucociliary differentiation, and PneumoCult-ALI medium with manufactuer’s supplements (STEMCELL) and Primocin (InvivoGen) was added to the basal chamber. From week 2 following air- exposure, mucus was gently washed from the apical surface with warmed PBS and stored for further analysis. Cells were maintained in ALI culture for 21 days, then inserts were fixed in 4% PFA (Electron Microscopy Sciences) for immunofluorescence microscopy.</p></sec></sec><sec id="S21"><title>Flow cytometry of cultured PBECs</title><p id="P34">Cultured primary airway epithelial cells (passage #3) were plated in a 96-well round bottomed plate (2 x 10<sup><xref ref-type="bibr" rid="R5">5</xref></sup>/ well). Cells were washed in PBS (Gibco), centrifuged (500<italic>xg</italic>, 4°C, 5 minutes) and the pellet resuspended in LIVE/DEAD fixable near-IR dead cell stain (1:1000 dilution in PBS; #L10119; Invitrogen). After a 20-minute incubation in the dark at room temperature, excess viability dye was removed with a PBS wash. Intracellular fixation and permeabilization buffer (eBioscience) was added to the cells overnight at 4°C in the dark. Cells were washed in PBS and stained with 150 μl unconjugated primary antibody anti-p63 and Human Fc block (1:50; BD Pharmingen) diluted in permeabilization buffer (eBioscience) for 30 minutes at 4°C in the dark. Cells were washed in permeabilization buffer and centrifuged. Secondary antibody staining was performed with Goat Anti-Rabbit IgG conjugated to BV421 (1:200; BD) diluted with permeabilization buffer in 2% BSA. Cells were washed and stained with remaining conjugated primary antibodies to EpCAM/ CD326, CD45 and KRT5 diluted in permeabilization buffer for 30 minutes at 4°C in the dark. After a final washing step, the cells were resupended in FACS buffer. Flow cytometry was performed using a BD LSR Fortessa III cell analyser. FlowJo7 was used for data analysis.</p></sec><sec id="S22"><title>Isolation and culture of primary human lung fibroblasts (HLFs)</title><p id="P35">HLF were extracted from lung tissue specimens using an established protocol<sup><xref ref-type="bibr" rid="R72">72</xref></sup>. Linear, parallel scratches were made with a scalpel on the surface of a 6- well culture plate to encourage fibroblast outgrowth. Lung tissue was cut into 1mm<sup><xref ref-type="bibr" rid="R3">3</xref></sup> fragments and evenly distributed within each well (5 pieces/well). HLFs were observed growing out of the tissue fragments after approximately 7 days in culture. Explant cultures were maintained in DMEM (supplemented with 20% FBS and Primocin) in an incubator (37°C, 5% CO<sub>2</sub>). Media was refreshed every 48 hours. Primary HLFs were passaged at 80% confluence and cryopreserved in DMEM with 10% DMSO and 10% FBS (passage #2). When required, HLFs were thawed quickly in a 37°C water bath and cultured in a 75cm<sup><xref ref-type="bibr" rid="R2">2</xref></sup> flask (Corning) until 80% confluent, then passaged for use in experiments (Table S3).</p></sec><sec id="S23"><title>Cell-derived matrices (CDMs) from primary HLFs</title><sec id="S24"><title>Generation of CDMs</title><p id="P36">The approach used to generate CDMs from primary HLFs was based on a protocol published by Kaukonen et al.<sup><xref ref-type="bibr" rid="R29">29</xref></sup> HLFs isolated from IPF (<italic>n</italic>=3) and control (<italic>n</italic>=3) subjects were seeded (4.0 x 10<sup><xref ref-type="bibr" rid="R4">4</xref></sup>) in wells of a 24-well μ-plate (Ibidi). The cultures were maintained in DMEM (Gibco) media supplemented with 10% FBS (Sigma-Aldrich) and Primocin (InvivoGen) in an incubator (37°C, 5% CO<sub>2</sub>). The cells formed a confluent monolayer and media was replaced every 48 hours for 21 days to allow CDM production by HLFs. Medium was removed and the cells washed with PBS. HLFs were denuded by adding 500μl warmed sterile- extraction solution (1ml of NH<sub>4</sub>OH, 250μl of Triton-X-100 and 48.75ml PBS passed through a 0.45μm filter) for approximately 1 minute whilst closely observing the integrity of the matrix using a light microscope. The extraction buffer was gently removed and the CDM washed carefully with PBS to avoid disruption. Residual cellular DNA was removed by incubating CDMs (37°C, 30 minutes) with 500μl DNase I (10μg ml<sup>-1</sup>; Roche). The CDM was gently washed with PBS and matrix integrity was validated using a light-microscope. In contrast to the protocol described by Kaukonen et al.<sup><xref ref-type="bibr" rid="R29">29</xref></sup> we did not use gelatin-coated coverslips or ascorbic acid in the media to promote cross-linking of collagen, as did not want to artificially alter the properties of the matrix in a way that would influence cell migration or MS-proteomic results.</p></sec><sec id="S25"><title>Immunofluorescence microscopy</title><p id="P37">CDMs in a 24-well μ-plates (Ibidi) were gently washed in PBS and fixed in 10% formalin (Sigma-Aldrich) for 15 minutes at room temperature. The fixative was removed, CDMs were washed in PBS then blocked with 30% horse serum (Gibco) for 1 hour at room temperature. CDMs were stained overnight at 4°C with primary antibodies to ECM constituent’s collagen I and fibronectin. After careful washing in PBS, secondary antibodies diluted in 30% horse serum were added for 30 minutes at room temperature. To validate the decellularization procedure, the secondary antibody used was goat anti-rabbit IgG conjugated to Alexa Fluor 546 (1:200; Invitrogen). For the cell migration experiments, the secondary antibody used was goat anti-mouse Alexa fluor 568 (1:200; Invitrogen). In both experiments Phalloidin-iFluor 488 (Abcam) was used as per manufacturer’s instructions and nuclei were counterstained with DAPI (1:1000; Sigma-Aldrich) for 20 minutes. The staining solution was removed from each well and Vectashield Antifade Mounting Medium was added. Imaging was carried out using a 63x oil objective on a Leica SP5 inverted confocal microscope. Images were acquired using the LAS AF platform (Leica) and analysed using Fiji<sup><xref ref-type="bibr" rid="R69">69</xref></sup> software. The KRT5<sup>+</sup> cell shown (yellow) migrating on fibronectin (magenta) in <xref ref-type="fig" rid="F5">Fig. 5b</xref>, was imaged on a Leica SP8 confocal, with LAS X software, using a 20x/0.75NA Plan Apo lens. The figure was created in Icy<sup><xref ref-type="bibr" rid="R73">73</xref></sup>.</p></sec></sec><sec id="S26"><title>KRT5+ cell migration experiments</title><sec id="S27"><title>KRT5+ cell migration on ECM ligands</title><p id="P38">Tissue culture plates (48-well, Corning) were coated with purified human collagen type I (Sigma-Aldrich, #CC050), type III (Sigma-Aldrich, #CC054), type IV (Sigma-Aldrich, #C6745) or recombinant human versican (RayBiotech, #230-00833-50) at a concentration of 50μg/ml, for 1 hour (37°C, 5% CO<sub>2</sub>) in line with previously published methods from our lab<sup><xref ref-type="bibr" rid="R21">21</xref></sup>. KRT5+ cells from healthy controls and IPF patients were seeded (2.5 x 10<sup><xref ref-type="bibr" rid="R3">3</xref></sup>) into each well and after 30 minutes to adhere, were imaged with a 4x objective on the JuLI™ Stage Real-Time Cell History Recorder every 15 minutes for 48 hours. The JPEG images generated were imported to Nikon NIS Elements v.4.50 for analysis.</p></sec><sec id="S28"><title>KRT5+ cell migration through CDMs</title><p id="P39">KRT5+ cells were incubated with CellTracker™ Deep Red Dye staining solution (Invitrogen) for 40 minutes at 37°C. The cells were centrifuged (1200rpm, 5 minutes, 4°C), staining dye removed and resuspended in Airway Epithelial Cell Growth media (PromoCell). KRT5+ cells were added (1.0 x 10<sup><xref ref-type="bibr" rid="R4">4</xref></sup> cells / well) to decellurised CDMs in a 24-well μ-plate (Ibidi). The cells were incubated for 2 hours (37°C, 5% CO<sub>2</sub>) to allow the cells to adhere to the CDM. A Zeiss Axio Observer Z1 Inverted Widefield Microscope with Lumencor SpectraX LED illumination and Zen Blue acquisition software was used to image the fluorescently labelled cells. After plate calibration, Köhler illumination was adjusted, and positions in each well were added manually. Images were captured in the far-red channel (excitation 625–655 nm, emission 665–715 nm, for CellTracker DeepRed) and in transmitted light, using a Plan-Neofluar 10x/0.30 Ph1 objective. The system had a Hamamatsu Flash4.0 camera, and 2x2 binning was used, giving a 1024x1024 pixel image with a pixel size of 1.30 μm. Two positions with good cell coverage were manually selected per well, and their x, y and z coordinates saved. A Z-stack of five slices with a step of 7 μm was acquired for each position, covering 28 μm in total. The stacks were centred on the z value saved when selecting the position, and these Z-stacks were acquired every 5 minutes for 24 hours. To minimise subtle displacement of the delicate matrix in the well associated with stage-related turbulence in the culture media, the stage speed was reduced to 40%. At the end of the experiment the CDMs with adherent KRT5+ cells were fixed in 10% formalin for 15 minutes at room temperature, washed in PBS and stored at 4°C for subsequent immunofluorescent imaging.</p></sec></sec><sec id="S29"><title>Cell tracking analysis</title><sec id="S30"><title>KRT5+ cell migration on ECM ligands</title><p id="P40">The JPEG Images generated by the JuLI real-time cell history recorder were imported to Nikon NIS- Elements (Nikon Instruments Inc.) to create an image sequence and calibrated (1.13μm/ pixel in x and y). The sequence was then saved as a .nd2 file for processing and analysis. To remove any artefact associated with microscope drift, the sequence was aligned to the previous frame. A median filter with a kernel size of 9 was applied to improve accuracy of spot detection. Spot detection using the brightfield channel was set to detect dark spots with a typical diameter of 27μm and with a contrast setting of 8. Bright objects were removed. Once dark spots were detected, automated tracking was performed by the software algorithm ‘Track Binaries’ and then manually inspected as a means of quality control. False tracks such as those associated with debris or those which jumped to nearby cells were removed from the analysis. If overall tracking was deemed less than 90% accurate on the basis of manually checking the tracks, the sequence was excluded. The raw cell migration data generated by Nikon NIS software was exported to MotilityLab (<ext-link ext-link-type="uri" xlink:href="http://www.motilitylab.net/">http://www.motilitylab.net/</ext-link>) an online resource allowing the quantitative and statistical analyses of cell tracks, and GraphPad Prism v9.4.1 for further analysis and presentation. Only cells tracked for the entire 12-hour duration were included in the final analysis. For each cell the following measurements were reported; (1) track speed - track length divided by the time elapsed from the beginning to final position; (2) straightness ratio (directionality ratio) - calculated by the straight-line distance between the start and end point of the cell track, divided by the track length. A straight cell trajectory equates to a straightness ratio of 1, a curved trajectory equates to a ratio of 0; (3) mean squared displacement (MSD) - based on particle movement theory, can be used to characterise the type of motion displayed by cells<sup><xref ref-type="bibr" rid="R74">74</xref></sup> and measures the average distance travelled by a cell over a specified time interval. Nikon NIS-Elements calculates MSD as a sum of the squared distances from the beginning of the track.</p></sec><sec id="S31"><title>KRT5+ cell migration through CDMs</title><p id="P41">Images captured using the Cy5 and brightfield channels of the Zeiss Axio Observer were pre-processed in Icy<sup><xref ref-type="bibr" rid="R73">73</xref></sup>, an open source bioimage analysis software. Z-stack maximum intensity projection was performed on the 12-hour image sequence (144 frames, 5- minute intervals). In Nikon NIS- Elements the image sequence was calibrated (xy pixel size of 1.30 μm, and time step of 300secs) and images aligned to previous frame to correct for drift. Spot detection was performed on the Cy5 channel with the detector set to detect bright, circular objects of different sizes of typical diameter 27 μm with contrast set to 140. Dark objects were removed. Automated tracking was optimised using a random motion, constant speed model. A maximum gap size of 3 was allowed between tracks. Tracks were terminated when no object was closer than 2 times the standard deviation from a predicted position. A maximum object speed of 100 μm/s was set to exclude rapidly moving floating debris. Tracks with 12 or less frames were deleted. The automated tracks were manually checked for accuracy. The raw cell migration data generated by Nikon NIS-Elements software was exported to MotilityLab an online resource allowing the quantitative and statistical analyses of cell tracks, and GraphPad Prism v9.4.1 for further analysis and presentation. Only cells tracked for the entire 12-hour duration were included in the final analysis.</p></sec></sec><sec id="S32"><title>Immunofluorescence microscopy of KRT5+ cells</title><sec id="S33"><title>Submerged culture</title><p id="P42">KRT5+ cells in media (PromoCell, supplemented as previously) were seeded (3.0 x 10<sup><xref ref-type="bibr" rid="R4">4</xref></sup>/ well) on a collagen I (PureCol®, Advanced BioMatrix) coated 96-well μ-plate (Ibidi). When confluent, the cells were fixed in 4% PFA for 20 minutes, washed in PBS, then permeabilised with permeabilisation buffer (eBioscience) for 20 minutes (room temperature). The cells were blocked with 2% BSA in PBS for 30 minutes (room temperature) then incubated with primary conjugated antibodies to KRT5 overnight at 4°C. Cell nuclei were counterstained with DAPI (1:2000 dilution). Imaging was carried out with a Leica SP5 inverted confocal microscope. Images were acquired using LAS AF (Leica) and analysed using Fiji software<sup><xref ref-type="bibr" rid="R69">69</xref></sup>.</p></sec><sec id="S34"><title>High-resolution Airyscan microscopy</title><p id="P43">UV-sterilised glass coverslips were pre-coated in ECM proteins as previously described. KRT5+ cells were seeded at a density of 1.0 x 10<sup><xref ref-type="bibr" rid="R4">4</xref></sup> cells per well. After 24 hours of incubation these cells were fixed in 4% formaldehyde (Electron Microscopy Sciences). Phalloidin Alexa Fluor 488 (Invitrogen) was used to stain actin cytoskeleton and DAPI as a nuclear counterstain. The cells were coverslip mounted with ProLong Gold Antifade Mountant (Invitrogen). High-resolution images were acquired using a 40x 1.3 NA oil objective on Zeiss 880 microscope using Airyscan detector (Beatson Institute, Glasgow, UK). Airyscan image processing was carried out using default settings in Zeiss Zen black.</p></sec></sec><sec id="S35"><title>Wound healing PCR array</title><p id="P44">KRT5+ cells were lysed by the addition of 350μl Buffer RLT (QIAGEN) containing 1% ß-mercaptoethanol (β-ME). RNA was extracted using the RNeasy MiniKit (QIAGEN) as per manufacturer’s instructions. RNA concentration and RNA integrity number (RIN) was confirmed using 1μl of the RNA sample with the Agilent RNA ScreenTape assay and Agilent 2200 TapeStation instrument and software, as per manufacturer’s protocol.</p><p id="P45">The expression of a panel of genes involved in wound healing pathways, was evaluated by real-time RT-PCR using an RT<sup><xref ref-type="bibr" rid="R2">2</xref></sup> Profiler PCR Array (#PAHS-121Z; QIAGEN) in a 96-well plate format. Each plate contained primer assays for 84 wound healing genes and 5 housekeeping genes for normalisation of the data. They also incorporated controls to test for genomic DNA contamination, and the efficiency of the reverse-transcription and PCR reactions. A total of 300ng RNA from each sample was used to synthesise cDNA with the RT<sup><xref ref-type="bibr" rid="R2">2</xref></sup> First Strand Kit (QIAGEN), incubating at 42°C for 15 minutes, then at 95°C for 5 minutes in a Veriti 96-well Thermal Cycler (Applied Biosciences). The cDNA was mixed with the SYBR Green ROX qPCR Mastermix (QIAGEN) and aliquoted into the wells of the RT<sup><xref ref-type="bibr" rid="R2">2</xref></sup> Profiler PCR Array. PCR was performed on a ViiA 7 instrument (Applied Biosystems) using Fast 96-well block. The following cycling conditions were programmed; 1 cycle at 95°C for 10 minutes; 40 cycles at 95°C for 15 seconds and 60°C for 1 minute, with a ramp rate adjusted to 1°C/s. The real-time PCR threshold cycle (CT) values were analysed using the GeneGlobe Data Analysis Center (Qiagen). Within this software, sample quality control was performed, and the housekeeping gene(s) displaying smallest variance across samples was selected. A C<sub>T</sub> cut-off of 35 was set for the analysis. Normalised gene expression values are calculated as the difference between the C<sub>T</sub> value of the gene of interest (GOI) and the average C<sub>T</sub> value of the selected housekeeping genes (HKG): <disp-formula id="FD1"><mml:math id="M1"><mml:msup><mml:mtext>2</mml:mtext><mml:mrow><mml:mtext>-</mml:mtext><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msub><mml:mtext>C</mml:mtext><mml:mtext>T</mml:mtext></mml:msub><mml:msub><mml:mrow><mml:mtext>(GOI)-C</mml:mtext></mml:mrow><mml:mtext>T</mml:mtext></mml:msub><mml:mtext>(AVGHKG)</mml:mtext></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:msup><mml:msup><mml:mtext>=2</mml:mtext><mml:mrow><mml:msub><mml:mrow><mml:mtext>-ΔC</mml:mtext></mml:mrow><mml:mtext>T</mml:mtext></mml:msub></mml:mrow></mml:msup></mml:math></disp-formula></p><p id="P46">Fold- change is calculated using the delta delta CT method<sup><xref ref-type="bibr" rid="R75">75</xref></sup> by dividing the normalised expression in IPF samples by the normalised expression in healthy control samples: <disp-formula id="FD2"><mml:math id="M2"><mml:mfrac><mml:mrow><mml:msup><mml:mtext>2</mml:mtext><mml:mrow><mml:msub><mml:mrow><mml:mtext>-ΔC</mml:mtext></mml:mrow><mml:mtext>T(IPF)</mml:mtext></mml:msub></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mtext>2</mml:mtext><mml:mrow><mml:msub><mml:mrow><mml:mtext>-ΔC</mml:mtext></mml:mrow><mml:mrow><mml:mtext>T(CON)</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:msup><mml:mtext>=2</mml:mtext><mml:mrow><mml:msub><mml:mrow><mml:mtext>-ΔΔC</mml:mtext></mml:mrow><mml:mtext>T</mml:mtext></mml:msub></mml:mrow></mml:msup></mml:math></disp-formula></p><p id="P47">A Student's t-test of the replicate normalised gene expression values for each gene in the IPF group and healthy control groups was performed. PCA and hierarchical clustering was performed in ClustVis<sup><xref ref-type="bibr" rid="R76">76</xref></sup>, and volcano plots were generated using VolcaNoseR<sup><xref ref-type="bibr" rid="R77">77</xref></sup>.</p></sec><sec id="S36"><title>Mass spectrometry (MS)- based proteomics</title><sec id="S37"><title>Isolation of enriched cell-derived ECM and MS sample preparation</title><p id="P48">A method developed by Lennon et al<sup><xref ref-type="bibr" rid="R35">35</xref></sup> was used to reduce the complexity of protein samples for MS analysis by removing cellular components and enriching for ECM proteins. All steps were carried out at 4°C to minimise proteolysis. Primary HLFs from 6 donors (<italic>n</italic> = 3 controls, <italic>n</italic> = 3 IPF) were cultured in a 10cm<sup><xref ref-type="bibr" rid="R2">2</xref></sup> petri dish and maintained for 21 days in DMEM (Gibco) and 10% FBS to allow matrix deposition. Following a PBS wash, the cells were incubated for 30 minutes in extraction buffer (10 mM Tris, 150 mM NaCl, 1% [vol/vol] Triton X-100, 25mMEDTA, protease inhibitor) to solubilise cellular proteins, and samples were then centrifuged at 14,000xg for 10 minutes. The remaining pellet was incubated for 30 minutes in alkaline detergent buffer (20 mM NH4OH and 0.5% [vol/vol] Triton X-100 in PBS) to further solubilise cellular proteins and disrupt cell–ECM interactions. Samples were then centrifuged at 14,000xg for 10 minutes. The remaining pellet was resuspended in S trap lysis buffer (5% SDS with 50 mM TEAB pH 7.5) and transferred to a 130 μl AFA tube (Covaris Inc, Woburn, USA,Covaris) to yield the ECM fraction. The lysate was further solubilised using AFA sonication in a Covaris LE220+ (Woburn, Massachusetts). Sample were disrupted for 300s, with 50 cycles per burst, a duty factor of 20% and a peak incident power of 500W.</p></sec><sec id="S38"><title>Western blotting</title><p id="P49">Proteins were resolved based on molecular weight using SDS-PAGE. Briefly, 2μl of 5x SDS-PAGE loading buffer was added to 10μl of sample, incubated for 10 mins at 95°C and loaded onto a precast NuPAGE 4-12% BisTris gel (ThermoFisher). The gel was run at 200V for 40-50 minutes. The proteins were transferred (30V for 70 minutes) to a nitrocellulose membrane (Whatman). InstantBlue (Sigma-Aldrich) Coomassie staining was used to visualise the proteins. Membranes were blocked in casein blocking buffer overnight at 4°C, then probed with primary antibodies to Lamin B1 (#12586; Cell Signalling), fibronectin (#F3648; Sigma-Aldrich) and α-tubulin (#T6199; Sigma-Aldrich) diluted in PBS with 0.05% (vol/vol) Tween20 (PBS-Tween) for 1 hour. Membranes were washed in PBS-Tween before adding secondary antibodies; goat anti-rabbit IgG (H+L) Alexa Fluor 680 (#10585543; ThermoFisher), anti-mouse IgG (H+L) DyLight 800 4X PEG conjugate (#5257; Cell Signaling) diluted in Milli-Q Ultrapure water for 1 hour. Membranes were washed in PBS-Tween then scanned using an Odyssey infrared (IR) imaging system (LI-COR Biosciences).</p></sec><sec id="S39"><title>S-Trap™ proteolytic digestion</title><p id="P50">The resulting ECM-enriched fractions were reduced in 5 mM dithiothreitol (DTT) and incubated for 10 minutes at 60°C to reduce the cysteine bonds. The samples were then alkylated in 15 mM iodoacetamide (IAM) for 30 minutes (in the dark). The alkylation reaction was finally quenched using 5 mM DTT. Aqueous phosphoric acid was added to the SDS lysates to a final concentration of 1.2% then S-Trap binding buffer (90% MeOH, 100 mM final TEAB, pH 7.1) was mixed with the acidified protein lysates. The acidified lysate/S-Trap buffer mix was loaded onto the S-Trap column. The captured proteins were washed centrifuging through 150 μl of S-Trap binding buffer at 4,000 g for 2 min and repeated three times. The proteins were digested by adding trypsin at a ratio of 1:10 wt:wt (enzyme:protein) to the top of the protein trap and incubated in an Eppendorf Thermomixer for 1 hr at 47°C. The peptides were eluted with 65 μl of digestion buffer (50 mM TEAB) from the S-Trap column and centrifuged at 4,000 g for 2 minutes then 65 μl of 0.1% aqueous formic acid (FA) was added and centrifuged at 4,000 g for 2 minutes. The remaining hydrophobic peptides were eluted with 30 μl of 30% aqueous acetonitrile containing 0.1% formic acid and centrifuged at 4,000 g for 2 minutes. All three elutions were combined and peptides were desalted using 1 mg of R3 beads which were placed in each well of a 96 well plate with 0.2 um PVDF membrane. R3 beads were washed with 50% (v/v) acetonitrile followed by 0.1 % (v/v) formic acid. Peptide samples were then resuspended in 5% (v/v) acetonitrile and 0.1% (v/v) formic acid to allow peptide binding to beads, washed twice with 0.1 % (v/v) formic acid, and peptides eluted in 50 % (v/v) acetonitrile, 0.1 % (v/v) formic acid. Peptides were desiccated in a vacuum centrifuge and resuspended in 10 μl of 5% (v/v) acetonitrile and 0.1% (v/v) formic acid.</p></sec><sec id="S40"><title>Data acquisition</title><p id="P51">Digested samples were analysed by LC-MS/MS using an UltiMate® 3000 Rapid Separation LC (RSLC, Dionex Corporation, Sunnyvale, CA) coupled to a QE HF (Thermo Fisher Scientific, Waltham, MA) mass spectrometer. Mobile phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in acetonitrile and the column used was a 75 mm x 250 μm i.d. 1.7μM CSH C18, analytical column (Waters).</p><p id="P52">A 1 μl aliquot of the sample was transferred to a 5μl loop and loaded onto the column at a flow of 300nl/min for 5 minutes at 5% B. The loop was then taken out of line and the peptides separated using a gradient that went from 5% to 7% B and from 300nl/min to 200nl/min in 1 minute followed by a shallow gradient from 7% to 18% B in 64 minutes, then from 18% to 27% B in 8 minutes and finally from 27% B to 60% B in 1 minute. The column was washed at 60% B for 3 minutes before re-equilibration to 5% B in 1 minutes. At 85 minutes the flow is increased to 300nl/min until the end of the run at 90min.</p><p id="P53">Mass spectrometry data was acquired in a data directed manner for 90 minutes in positive mode. Peptides were selected for fragmentation automatically by data dependant analysis on a basis of the top 12 peptides with m/z between 300 to 1750Th and a charge state of 2, 3 or 4 with a dynamic exclusion set at 15 sec. The MS Resolution was set at 120,000 with an AGC target of 3e6 and a maximum fill time set at 20ms. The MS2 Resolution was set to 30,000, with an AGC target of 2e5, a maximum fill time of 45 ms, isolation window of 1.3Th and a collision energy of 28.</p></sec><sec id="S41"><title>Data analysis</title><p id="P54">Raw MS files were imported into Proteome Discoverer v2.4.1.15 SP1 (PD) (Thermo Scientific), a program that integrates all the different steps in a quantitative proteomics experiment (including MS/MS spectrum extraction, peptide identification and quantification) into automated workflows. The data were analysed using the standard Sequest™ HT-Percolator workflow and the default consensus workflow for label-free quantification. The Sequest HT search was performed against the Homo sapiens database (SwissProt and TrEMBL version 2017-10-25, taxonomy 9606, 42252 and 124124 sequences respectively).</p><p id="P55">The hierarchical clustering of the proteomic data and the principal component analysis plots were computed and visualised using ClustVis<sup><xref ref-type="bibr" rid="R76">76</xref></sup>. Proteome Discoverer uses the ANOVA method to calculate the statistical significance of differential protein expression between sample groups, with a lower p-value indicating the abundances are likely to be statistically different. The Benjamini- Hochberg procedure was used to adjust for multiple comparisons. Protein interaction network analysis was performed using STRING v11 (<ext-link ext-link-type="uri" xlink:href="https://string-db.org/">https://string-db.org/</ext-link>), a database of known and predicted protein-protein interactions. The list of matrix proteins identified, and their respective fold change (based on calculated abundance ratios) were submitted to the search under proteins with values/ranks. The proteins were mapped onto the <italic>Homo sapiens</italic> network, with a FDR stringency of 1%. The active interaction sources selected were experiments and co-expression databases and the network edges represents the confidence (strength of data support). A medium confidence score of 0.4 was applied.</p><p id="P56">The sample preparation and mass spectrometry analysis was supported by the Biological Mass Spectrometry (BioMS) facility in the Faculty of Biology, Medicine and Health of the University of Manchester.</p></sec></sec><sec id="S42"><title>Statistics and reproducibility</title><p id="P57">Statistical analysis was carried out using GraphPad Prism v9.4.1 (GraphPad Software, LLC.). To determine if the data was from a Gaussian distribution the D’Agostino-Pearson omnibus normality test was performed. If the p- value returned for this test was high (&gt;0.05), it was assumed the data were sampled from a Gaussian distribution and a parametric test was used for statistical analysis; for unpaired data this was an unpaired t test, and for paired data this was a paired t-test. If the normality test p-value was ≤0.05, the null hypothesis was rejected and therefore data were not sampled from a Gaussian distribution so a nonparametric test was used; for unpaired data this was a Mann-Whitney test and for paired data this was a Wilcoxon matched-pairs signed rank test. For cell migration experiments where multiple cells from multiple donors were studied under different experimental conditions, a nested one-way ANOVA with Tukey’s multiple comparison test was used. For quantitative analysis of SHG data acquired from different lung regions from multiple IPF and control donors, an ordinary one-way ANOVA with Tukey’s multiple comparisons test was performed. For correlation analyses, Pearson correlation coefficients were computed and a two-tailed P value, ≤0.05 considered significant. The statistical test used for each analysis are described in the accompanying figure legend and significant differences noted by asterisk(s): *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001.</p></sec><sec id="S43"><title>Resources</title><table-wrap id="T4" position="anchor" orientation="portrait"><table frame="box" rules="all"><thead><tr style="background-color:#e7e6e6"><th align="left" valign="top">REAGENT or RESOURCE</th><th align="left" valign="top">SOURCE</th><th align="left" valign="top">IDENTIFIER</th></tr></thead><tbody><tr style="background-color:#e7e6e6"><td align="left" valign="top" colspan="3">Antibodies</td></tr><tr><td align="left" valign="top">Rabbit monoclonal to Cytokeratin 5 (clone EP1601Y), unconjugated</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">Cat# ab52635, RRID:AB_869890</td></tr><tr><td align="left" valign="top">Rabbit monoclonal to Cytokeratin 5 (clone EP1601Y), AF 647</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">Cat# ab193895, RRID:AB_2728796</td></tr><tr><td align="left" valign="top">Rabbit polyclonal to Cytokeratin 5 (clone Poly19055), unconjugated</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 905501, RRID:AB_2565050</td></tr><tr><td align="left" valign="top">Goat polyclonal Anti-Collagen Type I – 169Tm</td><td align="left" valign="top">Standard BioTools Inc.</td><td align="left" valign="top">Cat# 3169023D, RRID:AB_2810857</td></tr><tr><td align="left" valign="top">Rabbit polyclonal Anti-Collagen Type I, unconjugated</td><td align="left" valign="top">Novus Biologicals</td><td align="left" valign="top">Cat# NB600-408, RRID:AB_343276</td></tr><tr><td align="left" valign="top">Mouse monoclonal Anti-Collagen Type I (clone COL-1), unconjugated</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat# C2456, RRID:AB_476836</td></tr><tr><td align="left" valign="top">Rabbit polyclonal Anti-Collagen Type III alpha 1, unconjugated</td><td align="left" valign="top">Novus Biologicals</td><td align="left" valign="top">Cat# NB600-594, RRID:AB_530879</td></tr><tr><td align="left" valign="top">Rabbit polyclonal Anti-Collagen Type IV, unconjugated</td><td align="left" valign="top">Novus Biologicals</td><td align="left" valign="top">Cat# NB120-6586, RRID:AB_789360</td></tr><tr><td align="left" valign="top">Recombinant rabbit monoclonal Anti-versican antibody (clone EPR12277), unconjugated</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">Cat# ab240200</td></tr><tr><td align="left" valign="top">Rabbit polyclonal Anti-fibronectin, unconjugated</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">Cat# ab2413, RRID:AB_2262874</td></tr><tr><td align="left" valign="top">Mouse monoclonal Anti-fibronectin (clone FN-15), unconjugated</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat# F7387, RRID:AB_476988</td></tr><tr><td align="left" valign="top">Mouse monoclonal to alpha-smooth muscle actin (clone 1A4), Cy3</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat# C6198, RRID:AB_476856</td></tr><tr><td align="left" valign="top">Mouse anti-Histone H3 (C-terminus) (clone 1B1-B2), AF 594</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 819405, RRID:AB_2715800</td></tr><tr><td align="left" valign="top">Rabbit monoclonal Anti-p63 (clone EPR5701), unconjugated</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">Cat# ab124762, RRID:AB_10971840</td></tr><tr><td align="left" valign="top">Mouse monoclonal Anti-human CD326/ EpCAM (clone 9C4), AF 488</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 324209, RRID:AB_756083</td></tr><tr><td align="left" valign="top">Mouse monoclonal Anti-human CD45 (clone H130), BV 605</td><td align="left" valign="top">BioLegend</td><td align="left" valign="top">Cat# 304042, RRID:AB_2562106</td></tr><tr><td align="left" valign="top">Rabbit monoclonal Anti-Lamin B1 (clone D4Q4Z), unconjugated</td><td align="left" valign="top">Cell Signalling</td><td align="left" valign="top">Cat# 12586, RRID:AB_2650517</td></tr><tr><td align="left" valign="top">Rabbit polyclonal Anti-Fibronectin, unconjugated</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat# F3648, RRID:AB_476976</td></tr><tr><td align="left" valign="top">Goat anti-rabbit IgG (H+L), AF 680</td><td align="left" valign="top">ThermoFisher</td><td align="left" valign="top">Cat# 10585543</td></tr><tr><td align="left" valign="top">Goat anti-mouse IgG (H+L), DyLight 800 4X PEG Conjugate</td><td align="left" valign="top">Cell Signalling</td><td align="left" valign="top">Cat# 5257</td></tr><tr><td align="left" valign="top">Goat anti-rabbit IgG, DyLight 488</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat# 35552</td></tr><tr><td align="left" valign="top">Goat anti-rabbit IgG, AF 647</td><td align="left" valign="top">ThermoFisher</td><td align="left" valign="top">Cat# A-21244</td></tr><tr><td align="left" valign="top">Goat anti-mouse IgG, AF 546</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat# A-11030</td></tr><tr><td align="left" valign="top">Goat anti-mouse IgG, AF 568</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat# A-11004</td></tr><tr><td align="left" valign="top">Goat Anti-Rabbit IgG, BV421</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">Cat# 565014</td></tr><tr style="background-color:#e7e6e6"><td align="left" valign="top" colspan="3">Biological samples</td></tr><tr><td align="left" valign="top">Lung tissue sections from controls</td><td align="left" valign="top">Royal Brompton Hospital, UK</td><td align="left" valign="top">See Table S1</td></tr><tr><td align="left" valign="top">Lung tissue sections from patients with IPF</td><td align="left" valign="top">Royal Brompton Hospital, UK</td><td align="left" valign="top">See Table S1</td></tr><tr><td align="left" valign="top">KRT5+ basal cells (BCs) derived from primary bronchial epithelial cells (airway brushings) from healthy controls Royal Brompton</td><td align="left" valign="top">Hospital, UK</td><td align="left" valign="top">See Table S3</td></tr><tr><td align="left" valign="top">KRT5+ basal cells (BCs) derived from primary bronchial epithelial cells (airway brushings) from patients with IPF</td><td align="left" valign="top">Royal Brompton Hospital, UK</td><td align="left" valign="top">See Table S3</td></tr><tr><td align="left" valign="top">Primary human lung fibroblasts (HLFs) from controls</td><td align="left" valign="top">Royal Brompton Hospital, UK</td><td align="left" valign="top">See Table S3</td></tr><tr><td align="left" valign="top">Primary human lung fibroblasts (HLFs) from patients with IPF</td><td align="left" valign="top">Royal Brompton Hospital, UK</td><td align="left" valign="top">See Table S3</td></tr><tr style="background-color:#e7e6e6"><td align="left" valign="top" colspan="3">Chemicals, peptides, and recombinant proteins</td></tr><tr><td align="left" valign="top">Gentaclear</td><td align="left" valign="top">Genta Medical, UK</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">DAPI</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat# D9542</td></tr><tr><td align="left" valign="top">ProLong Gold antifade mountant</td><td align="left" valign="top">Life Technologies</td><td align="left" valign="top">Cat# P36934</td></tr><tr><td align="left" valign="top">Vectashield Antifade Mounting Medium</td><td align="left" valign="top">Vector Laboratories</td><td align="left" valign="top">Cat# H-1000-10</td></tr><tr><td align="left" valign="top">Dako Target Retrieval Solution</td><td align="left" valign="top">Agilent</td><td align="left" valign="top">Cat# S-236784-2</td></tr><tr><td align="left" valign="top">PureCol Type 1 Collagen Solution</td><td align="left" valign="top">Advanced BioMatrix</td><td align="left" valign="top">Cat# 5005</td></tr><tr><td align="left" valign="top">16% Paraformaldehyde</td><td align="left" valign="top">Electron Microscopy Sciences</td><td align="left" valign="top">Cat# RT-15710</td></tr><tr><td align="left" valign="top">LIVE/DEAD fixable near-IR dead cell stain</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat# L10119</td></tr><tr><td align="left" valign="top">Intracellular fixation and permeabilization buffer</td><td align="left" valign="top">eBioscience</td><td align="left" valign="top">Cat# 88-8824-00</td></tr><tr><td align="left" valign="top">Permeabilisation buffer 10X</td><td align="left" valign="top">eBioscience</td><td align="left" valign="top">Cat# 00-8333-56</td></tr><tr><td align="left" valign="top">Human Fc block</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">Cat# 564219</td></tr><tr><td align="left" valign="top">Primocin</td><td align="left" valign="top">InvivoGen</td><td align="left" valign="top">Cat# ant-pm-1</td></tr><tr><td align="left" valign="top">DNase I</td><td align="left" valign="top">Roche</td><td align="left" valign="top">Cat# 10104159001</td></tr><tr><td align="left" valign="top">10% formalin</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat# HT5011-ICS</td></tr><tr><td align="left" valign="top">Phalloidin-iFluor 488</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">Cat# ab176753</td></tr><tr><td align="left" valign="top">Purified human collagen type I</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat# CC050</td></tr><tr><td align="left" valign="top">Purified human collagen type III</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat# CC054</td></tr><tr><td align="left" valign="top">Purified human collagen type IV</td><td align="left" valign="top">Sigma-Aldrich</td><td align="left" valign="top">Cat# C6745</td></tr><tr><td align="left" valign="top">Recombinant human versican</td><td align="left" valign="top">RayBiotech</td><td align="left" valign="top">Cat# 230-00833-50</td></tr><tr><td align="left" valign="top">CellTracker™ Deep Red Dye</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">Cat# C34565</td></tr><tr><td align="left" valign="top">Buffer RLT</td><td align="left" valign="top">Qiagen</td><td align="left" valign="top">Cat# 79216</td></tr><tr><td align="left" valign="top">InstantBlue</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">Cat#119211</td></tr><tr><td align="left" valign="top">Sequencing Grade modified Trypsin</td><td align="left" valign="top">Promega</td><td align="left" valign="top">Cat# V5113</td></tr><tr><td align="left" valign="top">OLIGO™ R3 Reversed - Phase Resin</td><td align="left" valign="top">ThermoFisher</td><td align="left" valign="top">Cat# 1133903</td></tr><tr style="background-color:#e7e6e6"><td align="left" valign="top" colspan="3">Critical commercial assays</td></tr><tr><td align="left" valign="top">Maxpar X8 Antibody Labeling Kit</td><td align="left" valign="top">Standard BioTools Inc.</td><td align="left" valign="top">Cat# 201151B</td></tr><tr><td align="left" valign="top">Maxpar® X8 Antibody Labeling Kit, 147 Sm</td><td align="left" valign="top">Standard BioTools inc.</td><td align="left" valign="top">Cat# 201147A</td></tr><tr><td align="left" valign="top">Maxpar® X8 Antibody Labeling Kit, 153 Eu</td><td align="left" valign="top">Standard BioTools inc.</td><td align="left" valign="top">Cat# 201153A</td></tr><tr><td align="left" valign="top">Maxpar® X8 Antibody Labeling Kit, 164 Dy</td><td align="left" valign="top">Standard BioTools inc.</td><td align="left" valign="top">Cat# 201164A</td></tr><tr><td align="left" valign="top">Maxpar® X8 Antibody Labeling Kit, 176 Yb</td><td align="left" valign="top">Standard BioTools inc.</td><td align="left" valign="top">Cat# 201176A</td></tr><tr><td align="left" valign="top">RT<sup><xref ref-type="bibr" rid="R2">2</xref></sup> First Strand Kit</td><td align="left" valign="top">Qiagen</td><td align="left" valign="top">Cat# 330401</td></tr><tr><td align="left" valign="top">Wound healing RT<sup><xref ref-type="bibr" rid="R2">2</xref></sup> Profiler PCR Array</td><td align="left" valign="top">Qiagen</td><td align="left" valign="top">Cat# PAHS-121Z</td></tr><tr style="background-color:#e7e6e6"><td align="left" valign="top" colspan="3">Deposited data</td></tr><tr><td align="left" valign="top">Mass spectrometry- proteomics</td><td align="left" valign="top">This paper</td><td align="left" valign="top">PRIDE, within the ProteomeXchange, PXD037236</td></tr><tr><td align="left" valign="top">Raw data, <xref ref-type="fig" rid="F1">Figures 1</xref> - <xref ref-type="fig" rid="F7">7</xref></td><td align="left" valign="top">This paper</td><td align="left" valign="top">Mendeley Data; <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.17632/t92wnj6r8s.1">http://dx.doi.org/10.17632/t92wnj6r8s.1</ext-link></td></tr><tr style="background-color:#e7e6e6"><td align="left" valign="top" colspan="3">Software and algorithms</td></tr><tr><td align="left" valign="top">CyTOF Software v7.0, MCD viewer v1.0.560.6</td><td align="left" valign="top">Standard BioTools Inc.</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">FlowJo v9</td><td align="left" valign="top">BD Life Sciences</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/solutions/flowjo">https://www.flowjo.com/solutions/flowjo</ext-link></td></tr><tr><td align="left" valign="top">GraphPad Prism Version 9.4.1</td><td align="left" valign="top">GraphPad Software, LLC.</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</ext-link></td></tr><tr><td align="left" valign="top">Fiji v1.52p</td><td align="left" valign="top">Schindelin et al.</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="http://fiji.sc">http://fiji.sc</ext-link></td></tr><tr><td align="left" valign="top">Leica Application Suite X - LAS X</td><td align="left" valign="top">Leica Biosystems</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">ZEN 2.3 (Black edition)</td><td align="left" valign="top">ZEISS</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Imaris v9.6.0</td><td align="left" valign="top">Oxford Instruments</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://imaris.oxinst.com/packages">https://imaris.oxinst.com/packages</ext-link></td></tr><tr><td align="left" valign="top">OrientationJ plugin for Image J</td><td align="left" valign="top">Biomedical Image Group, EPFL, Switzerland</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="http://bigwww.epfl.ch/demo/orientation/">http://bigwww.epfl.ch/demo/orientation/</ext-link></td></tr><tr><td align="left" valign="top">Grey-level co-occurrence matrix (GLCM) texture plugin for Image J</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://imageJ.nih.gov/ij/plugins/texture.html">https://imageJ.nih.gov/ij/plugins/texture.html</ext-link>)</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Aperio ImageScope</td><td align="left" valign="top">Leica Biosystems</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Icy</td><td align="left" valign="top">de Chaumont F et al.</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://icy.bioimageanalysis.org/">https://icy.bioimageanalysis.org/</ext-link></td></tr><tr><td align="left" valign="top">Nikon NIS Elements v.4.50</td><td align="left" valign="top">Nikon Instruments Inc.</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">MotilityLab</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="http://www.motilitylab.net/">http://www.motilitylab.net/</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">GeneGlobe Data Analysis Center</td><td align="left" valign="top">Qiagen</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://geneglobe.qiagen.com/it/analyze">https://geneglobe.qiagen.com/it/analyze</ext-link></td></tr><tr><td align="left" valign="top">ClustVis</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://biit.cs.ut.ee/clustvis/">https://biit.cs.ut.ee/clustvis/</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">VolcaNoseR</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://huygens.science.uva.nl/VolcaNoseR/">https://huygens.science.uva.nl/VolcaNoseR/</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">STRING v11</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://string-db.org/">https://string-db.org/</ext-link></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Proteome Discoverer v2.4.1.15 SP1 (PD)</td><td align="left" valign="top">Thermo Scientific</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">BioRender.com</td><td align="left" valign="top">BioRender</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://biorender.com/">https://biorender.com/</ext-link></td></tr><tr><td align="left" valign="top">ImageJ</td><td align="left" valign="top">Schneider et al.</td><td align="left" valign="top"><ext-link ext-link-type="uri" xlink:href="https://imagej.net/">https://imagej.net/</ext-link></td></tr><tr style="background-color:#e7e6e6"><td align="left" valign="top" colspan="3">Other</td></tr><tr><td align="left" valign="top">Cytology brushes</td><td align="left" valign="top">Olympus</td><td align="left" valign="top">Cat# BC-202D-3010</td></tr></tbody></table></table-wrap></sec></sec></sec><sec id="S44" sec-type="extended-data"><title>Extended Data</title><fig id="F8" position="anchor"><label>Extended data Fig. 1</label><caption><title>KRT5<sup>+</sup> BC distribution in the normal and fibrotic distal lung.</title><p id="P58">(a – h) Distal lung tissue sections from controls and IPF patients immunostained for basal cell marker KRT5<sup>+</sup> (green) and DAPI (blue). (a, b) In control lung tissue KRT5+ cells are found restricted to the distal airways (AW) and are absent from the alveolar tissue (ALV). (c, d) In IPF lung tissue, KRT5<sup>+</sup> cells are again seen in the distal airways in a typical configuration but are also located in (e, f) honeycomb cysts (HC), and (g, h) fibrotic interstitium (FIBRO). (i) Overview of normal distal lung tissue showing KRT5<sup>+</sup> cells (red) lining the airway but absent from the alveolar region. SHG signal (turquoise) in the peribronchial (PB) and perivascular (PVS) regions. Alpha-smooth muscle actin (yellow) outlining smooth muscle bands surrounding airways.</p></caption><graphic xlink:href="EMS158911-f008"/></fig><fig id="F9" position="anchor"><label>Extended data Fig. 2</label><caption><title>Quantitative image analysis of control and IPF distal lung</title><p id="P59">(a) Scree plot of % variances explained by each component (dimension) of PCA plot shown in <xref ref-type="fig" rid="F1">Fig. 1d</xref>. (b) Corr plot of variables contributing to each dimension of PCA. (c - d) Image texture analysis per region showing (c) inverse difference moment (IDM) and (d) angular second moment (ASM). Data plotted as mean + SEM. Each data point represents the average of 2 – 6 images per area per subject. Ordinary one-way ANOVA with Tukey’s multiple comparisons test ****<italic>P</italic>&lt;0.0001, ***<italic>P</italic>&lt;0.001, **<italic>P</italic>&lt;0.01, *p&lt;0.05.</p></caption><graphic xlink:href="EMS158911-f009"/></fig><fig id="F10" position="anchor"><label>Extended data Fig. 3</label><caption><title>IMC of distal lung tissue from controls and patients with IPF</title><p id="P60">Imaging mass cytometry (IMC) of perivascular region of distal lung tissue from normal control (n = 1; H&amp;E overview shown in top panel) showing distribution of ECM components; collagen I (blue), collagen III (magenta) and versican (green) (middle panel), collagen IV (turquoise) (bottom panel) in relation to KRT5<sup>+</sup> BCs (red). Representative image demonstrating key regions; blood vessel (BV) and alveolar (ALV).</p></caption><graphic xlink:href="EMS158911-f010"/></fig><fig id="F11" position="anchor"><label>Extended data Fig. 4</label><caption><title>KRT5+ basal cells co-localise with fibroblasts in the fibrotic niche.</title><p id="P61">(a) Overview of fibrotic, remodelled alveolar region of IPF lung with high-resolution image (white box) showing co-localisation of KRT5+ basal cells (red) with a-SMA+ fibroblasts (yellow). (b) High resolution image of fibrotic alveolar region of IPF lung showing co-localisation of KRT+ basal cells, a-SMA+ fibroblasts and SHG signal (cyan).</p></caption><graphic xlink:href="EMS158911-f011"/></fig><fig id="F12" position="anchor"><label>Extended data Fig. 5</label><caption><title>Human airway basal cell phenotyping.</title><p id="P62">(a, b) Flow cytometry phenotyping of primary human airway epithelial cells in submerged culture (passage 3) for basal cell markers KRT5 and p63. (c) Immunofluorescence microscopy for KRT5 in submerged culture.</p></caption><graphic xlink:href="EMS158911-f012"/></fig><fig id="F13" position="anchor"><label>Extended data Fig. 6</label><caption><title>Gene expression of IPF KRT5+ cells compared to healthy KRT5+ cells cultured on collagen I or IPF CDMs.</title><p id="P63">(a, b) Volcano plots showing gene expression changes determined by Qiagen RT<sup><xref ref-type="bibr" rid="R2">2</xref></sup> PCR Array between KRT5+ cells from IPF patients vs. healthy controls cultured on (a) collagen I or (b) IPF CDMs. Upregulated genes in IPF KRT5+ cells vs. control KRT5+ cells (red), downregulated genes in IPF KRT5+ cells vs. control KRT5+ cells (blue). Significance defined as log fold change &gt;2 or &lt;2, p&lt;0.05. P values were calculated based on a Student's t-test of the replicate normalised gene expression values (2^(-Delta CT)) for each gene in control and test groups. Housekeeping genes used -ACTB, B2M and RPLP0.</p></caption><graphic xlink:href="EMS158911-f013"/></fig><fig id="F14" position="anchor"><label>Extended data Fig. 7</label><caption><title>Influence of proteins identified by MS-proteomics on KRT5<sup>+</sup> cell migration.</title><p id="P64">(a– c) Box and whisker dot plots quantifying displacement of cells from starting position for KRT5+ cells cultured on (a) IGFBP5; (b) GAS6; and (c) FN1. A nested one-way anova and Tukey’s multiple comparison test used for statistical analysis.</p></caption><graphic xlink:href="EMS158911-f014"/></fig><table-wrap id="T1" position="anchor" orientation="portrait"><label>Extended data Table 1</label><caption><title>Lung tissue sections used for image analysis experiments.</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle">Sample ID</th><th align="center" valign="middle">Diagnosis</th><th align="center" valign="middle">Lung histology</th><th align="center" valign="middle">Age (yrs)</th><th align="center" valign="middle">Gender</th></tr></thead><tbody><tr><td align="center" valign="middle">CTRL TISSUE 1</td><td align="center" valign="middle">Control</td><td align="center" valign="middle">NSCLC; adenocarcinoma</td><td align="center" valign="middle">66</td><td align="center" valign="middle">F</td></tr><tr><td align="center" valign="middle">CTRL TISSUE 2</td><td align="center" valign="middle">Control</td><td align="center" valign="middle">NSCLC; pleomorphic carcinoma</td><td align="center" valign="middle">74</td><td align="center" valign="middle">M</td></tr><tr><td align="center" valign="middle">CTRL TISSUE 3</td><td align="center" valign="middle">Control</td><td align="center" valign="middle">NSCLC; pleomorphic carcinoma</td><td align="center" valign="middle">68</td><td align="center" valign="middle">M</td></tr><tr><td align="center" valign="middle">CTRL TISSUE 4</td><td align="center" valign="middle">Control</td><td align="center" valign="middle">NSCLC; pleomorphic carcinoma</td><td align="center" valign="middle">66</td><td align="center" valign="middle">F</td></tr><tr><td align="center" valign="middle">CTRL TISSUE 5</td><td align="center" valign="middle">Control</td><td align="center" valign="middle">NSCLC; adenocarcinoma</td><td align="center" valign="middle">64</td><td align="center" valign="middle">M</td></tr><tr><td align="center" valign="middle">IPF TISSUE 1</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">Usual interstitial pneumonia</td><td align="center" valign="middle">64</td><td align="center" valign="middle">F</td></tr><tr><td align="center" valign="middle">IPF TISSUE 2</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">Usual interstitial pneumonia</td><td align="center" valign="middle">63</td><td align="center" valign="middle">M</td></tr><tr><td align="center" valign="middle">IPF TISSUE 3</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">Usual interstitial pneumonia</td><td align="center" valign="middle">64</td><td align="center" valign="middle">M</td></tr><tr><td align="center" valign="middle">IPF TISSUE 4</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">Usual interstitial pneumonia</td><td align="center" valign="middle">64</td><td align="center" valign="middle">M</td></tr><tr><td align="center" valign="middle">IPF TISSUE 5</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">Usual interstitial pneumonia</td><td align="center" valign="middle">59</td><td align="center" valign="middle">M</td></tr><tr><td align="center" valign="middle">IPF TISSUE 6</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">Usual interstitial pneumonia</td><td align="center" valign="middle">57</td><td align="center" valign="middle">F</td></tr><tr><td align="center" valign="middle">IPF TISSUE 7</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">Usual interstitial pneumonia</td><td align="center" valign="middle">69</td><td align="center" valign="middle">M</td></tr><tr><td align="center" valign="middle">IPF TISSUE 8</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">Usual interstitial pneumonia</td><td align="center" valign="middle">77</td><td align="center" valign="middle">M</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="anchor" orientation="portrait"><label>Extended data Table 2</label><caption><title>Quantitative image analysis measurements</title></caption><table frame="void" rules="none"><thead><tr style="background-color:#a5a5a5"><th align="left" valign="top"><styled-content style="color:#ffffff">Measurement</styled-content></th><th align="left" valign="top"><styled-content style="color:#ffffff">Software</styled-content></th><th align="left" valign="top"><styled-content style="color:#ffffff">Description</styled-content></th></tr></thead><tbody><tr style="background-color:#e1e1e1"><td align="left" valign="top">Collagen intensity</td><td align="left" valign="top">Imaris Software, Oxford Instruments</td><td align="left" valign="top">Mean intensity of SHG signal in collagen fibres.</td></tr><tr style="background-color:#f0f0f0"><td align="left" valign="top">Collagen density</td><td align="left" valign="top">Imaris Software, Oxford Instruments</td><td align="left" valign="top">Collagen area represented as a percentage coverage of the total image area analysed.</td></tr><tr style="background-color:#e1e1e1"><td align="left" valign="top">Coherency</td><td align="left" valign="top">OrientationJ plugin, Fiji</td><td align="left" valign="top">Measures fibre orientation and coherency; a value of zero indicates perpendicular fibres, a value of 1 indicates parallel fibres.</td></tr><tr style="background-color:#f0f0f0"><td align="left" valign="top">Contrast</td><td align="left" valign="top">GLCM plugin, Fiji</td><td align="left" valign="top">Measures local variations in the greylevel co-occurrence matrix; a value of zero indicates a constant image with no variation.</td></tr><tr style="background-color:#e1e1e1"><td align="left" valign="top">Entropy</td><td align="left" valign="top">GLCM plugin, Fiji</td><td align="left" valign="top">Statistical measure of randomness, ranging from zero to infinity.</td></tr><tr style="background-color:#f0f0f0"><td align="left" valign="top">Correlation</td><td align="left" valign="top">GLCM plugin, Fiji</td><td align="left" valign="top">Linear dependency of grey levels on those of neighbouring pixels; higher values for similar grey-level regions.</td></tr><tr style="background-color:#e1e1e1"><td align="left" valign="top">Inverse Difference Moment (IDM)</td><td align="left" valign="top">GLCM plugin, Fiji</td><td align="left" valign="top">Local homogeneity or smoothness across an image; a value of 1 indicates a grey levels of the pixel pairs are similar</td></tr><tr style="background-color:#f0f0f0"><td align="left" valign="top">Angular Second Moment (ASM)</td><td align="left" valign="top">GLCM plugin, Fiji</td><td align="left" valign="top">Measures the number of repeated pixel pairs indicating uniformity of distribution of grey level in the image; a value of 1 indicates a constant image.</td></tr></tbody></table></table-wrap><table-wrap id="T3" position="anchor" orientation="portrait"><label>Extended data Table 3</label><caption><title>Catalogue of human primary cells used for the study.</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle"/><th align="center" valign="middle">Sample</th><th align="center" valign="middle">Cell type</th><th align="center" valign="middle">Diagnosis</th><th align="center" valign="middle">Age (yrs)</th><th align="center" valign="middle">Gender</th><th align="center" valign="middle">Smoking status</th></tr></thead><tbody><tr style="background-color:#d9d9d9"><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle"><bold><xref ref-type="fig" rid="F3">Fig. 3</xref></bold></td><td align="center" valign="middle">Con1</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">67</td><td align="center" valign="middle">M</td><td align="center" valign="middle">NA</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con2</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">65</td><td align="center" valign="middle">M</td><td align="center" valign="middle">NA</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con3</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">63</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Ex</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con4</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">55</td><td align="center" valign="middle">F</td><td align="center" valign="middle">Never</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con5</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">63</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Never</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF1</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">53</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Current</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF2</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">67</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Current</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF3</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">78</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Ex</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF4</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">76</td><td align="center" valign="middle">F</td><td align="center" valign="middle">Ex</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF5</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">68</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Ex</td></tr><tr style="background-color:#d9d9d9"><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle"><bold><xref ref-type="fig" rid="F4">Fig. 4</xref></bold></td><td align="center" valign="middle">Con1</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">26</td><td align="center" valign="middle">F</td><td align="center" valign="middle">Ex</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con2</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">51</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Ex</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con3</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">50</td><td align="center" valign="middle">F</td><td align="center" valign="middle">Never</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con4</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">47</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Ex</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF1</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">72</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Ex</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF2</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">73</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Never</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF3</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">80</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Never</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF4</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">80</td><td align="center" valign="middle">F</td><td align="center" valign="middle">Never</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF HLF for CDM</td><td align="center" valign="middle">HLF</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">67</td><td align="center" valign="middle">F</td><td align="center" valign="middle">NA</td></tr><tr style="background-color:#d9d9d9"><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle"><bold><xref ref-type="fig" rid="F5">Fig. 5</xref></bold></td><td align="center" valign="middle">Con1</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">67</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Ex</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con2</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">47</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Ex</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con3</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">26</td><td align="center" valign="middle">F</td><td align="center" valign="middle">Ex</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF1</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">52</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Ex</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF2</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">80</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Never</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF3</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">72</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Ex</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF HLF for CDM</td><td align="center" valign="middle">HLF</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">67</td><td align="center" valign="middle">F</td><td align="center" valign="middle">NA</td></tr><tr style="background-color:#d9d9d9"><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle"><bold><xref ref-type="fig" rid="F6">Fig. 6</xref></bold></td><td align="center" valign="middle">Con1</td><td align="center" valign="middle">HLF</td><td align="center" valign="middle">Normal tissue, carcinoid</td><td align="center" valign="middle">65</td><td align="center" valign="middle">F</td><td align="center" valign="middle">Never</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con2</td><td align="center" valign="middle">HLF</td><td align="center" valign="middle">Normal tissue, adenocarcinoma</td><td align="center" valign="middle">64</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Never</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con3</td><td align="center" valign="middle">HLF</td><td align="center" valign="middle">Normal tissue, adenocarcinoma</td><td align="center" valign="middle">66</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Ex</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF1</td><td align="center" valign="middle">HLF</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">67</td><td align="center" valign="middle">F</td><td align="center" valign="middle">NA</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF2</td><td align="center" valign="middle">HLF</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">51</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Never</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">IPF3</td><td align="center" valign="middle">HLF</td><td align="center" valign="middle">IPF</td><td align="center" valign="middle">62</td><td align="center" valign="middle">F</td><td align="center" valign="middle">NA</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Healthy KRT5+ BC</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">67</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Ex</td></tr><tr style="background-color:#d9d9d9"><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/><td align="center" valign="middle"/></tr><tr><td align="center" valign="middle"><bold><xref ref-type="fig" rid="F7">Fig. 7</xref></bold></td><td align="center" valign="middle">Con1</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">50</td><td align="center" valign="middle">F</td><td align="center" valign="middle">Never</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con2</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">47</td><td align="center" valign="middle">F</td><td align="center" valign="middle">Never</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con3</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">n/a</td><td align="center" valign="middle">n/a</td><td align="center" valign="middle">n/a</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con4</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">63</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Ex</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con5</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">55</td><td align="center" valign="middle">F</td><td align="center" valign="middle">Never</td></tr><tr><td align="center" valign="middle"/><td align="center" valign="middle">Con6</td><td align="center" valign="middle">KRT5+ BC</td><td align="center" valign="middle">Healthy</td><td align="center" valign="middle">63</td><td align="center" valign="middle">M</td><td align="center" valign="middle">Never</td></tr></tbody></table></table-wrap></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Extended Data</label><media xlink:href="EMS158911-supplement-Extended_Data.pdf" mimetype="application" mime-subtype="pdf" id="d31aAdIbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S45"><title>Acknowledgements</title><p>This work was supported by the Imperial College Faculty of Medicine Clinician-Investigator Scholarship Award and NHLI Clinical Lecturer award (R.J.H.); NIHR Imperial Biomedical Research Centre (BRC) Respiratory Shadow Theme project award P89068 (F.P.); Action for Pulmonary Fibrosis Mike Bray Fellowship (P.L.M.); Wellcome Senior Fellowship award 107059/Z/15/Z (C.M.L.); NIHR Clinician Scientist Fellowship CS-2013-13-017 and British Lung Foundation Chair in Respiratory Research C17-3 (T.M.M.); Wellcome Senior Fellowship award 202860/Z/16/Z (R.L.); Kidney Research UK grant RP_040_20180306 (M.F.); Wellcome Trust 203128/Z/16/Z (to the Wellcome Centre for Cell-Matrix Research at the University of Manchester); Cancer Research UK (CRUK) to the CRUK Beatson Institute A31287 (F.F. and L.M.C.) and core funding from CRUK A23983 (L.M.C.);. The Facility for Imaging by Light Microscopy (FILM) at Imperial College London is part-supported by funding from the Wellcome Trust grant 104931/Z/14/Z and BBSRC grant BB/L015129/1. We are grateful to the Beatson Advanced Imaging Resource for microscopy support. We thank clinical colleagues from the Royal Brompton Hospital Interstitial Lung Disease (ILD) Unit for supporting this work. We thank staff from Biological Mass Spectrometry Core Facility at the University of Manchester for their assistance. We thank Dr Ed Roberts (Cancer Research UK Beatson Institute, Glasgow, UK) for statistics advice. We thank Lorraine Lawrence of the Research Histology Facility (NHLI, Imperial College London) for her assistance. We thank the patients and healthy volunteers who generously donated samples for this study. We also acknowledge the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health</p></ack><sec id="S46" sec-type="data-availability"><title>Data and code availability</title><p id="P65">The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE<sup><xref ref-type="bibr" rid="R78">78</xref></sup> partner repository with the dataset identifier PXD037236.</p></sec><fn-group><fn id="FN1" fn-type="con"><p id="P66"><bold>Author Contributions</bold></p><p id="P67">Conceptualisation, R.J.H, A.J.B, T.M.M. and C.M.L.; Methodology, R.J.H., F.P., R.L., L.M.C., A.J.B. and C.M.L.; Formal Analysis, R.J.H., F.P., D.C.A.G., F.F., M.F.; Investigation, R.J.H., F.P., D.C.A.G., F.F., M.F., W.T., L.Y., S.A.W.; Resources, R.J.H., L.Y., S.A.W., P.L.M., S.V.K., A.N., A.R., and T.M.M; Writing – Original Draft, R.J.H., C.M.L., Writing – Review &amp; Editing, R.J.H., P.L.M., R.L., L.M.C., A.J.B., T.M.M. and C.M.L.; Funding Acquisition, R.J.H., C.M.L.; Supervision, A.J.B., T.M.M. and C.M.L.</p></fn><fn id="FN2" fn-type="conflict"><p id="P68"><bold>Competing interests</bold></p><p id="P69">P.L.M. received, unrelated to the submitted work, industry-academic funding from AstraZeneca via his institution and speaker and consultancy fees from Boehringer Ingelheim Trevi and Hoffman-La Roche. A.J.B. received, unrelated to the submitted work, consultancy fees and/or industry/academic funding from Ammax, Devpro, and Ionis pharmaceuticals, via his institution. A.G.N. is or has been a scientific advisor relating to IPF trials for Medical Quantitative Image Analysis, Galapagos, Boehringer Ingelheim and Roche, as well as receiving payment for educational activities relating to interstitial lung disease from Boehringer Ingelheim and UpToDate. T.M.M. received, unrelated to the submitted work, consultancy fees in relation to pulmonary fibrosis from Abbvie, Agomab, Apellis, Astra Zeneca, Bayer, Biogen Idec, Blade Therapeutics, BMS, Boehringer Ingelheim, Bridge Therapeutics, Carthronix, Chieisi, CohBar, CSLBehring, Daewoong, Daiatchi, DevPro, Endeavor, Fibrogen, Galapagos, Galecto, GlaxoSmithKline, Insilico, IQVIA, Kinevent, Pliant, Pfizer, Puretech, Qureight, Redx, Remedy Cell, Respivant Sciences, Roche, Shinogi, Surrozen, Theravance, Three Lakes Partners, Trevi, UCB, United Therapeutics, Veracyte, Vicore.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis</article-title><source>Science Advances</source><year>2020</year><volume>6</volume><elocation-id>eaba1983</elocation-id><pub-id pub-id-type="pmcid">PMC7439502</pub-id><pub-id pub-id-type="pmid">32832599</pub-id><pub-id pub-id-type="doi">10.1126/sciadv.aba1983</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habermann</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis</article-title><source>Science Advances</source><year>2020</year><volume>6</volume><elocation-id>eaba1972</elocation-id><pub-id pub-id-type="pmcid">PMC7439444</pub-id><pub-id pub-id-type="pmid">32832598</pub-id><pub-id pub-id-type="doi">10.1126/sciadv.aba1972</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyfman</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis</article-title><source>American journal of respiratory and critical care medicine</source><year>2018</year><pub-id pub-id-type="pmcid">PMC6580683</pub-id><pub-id pub-id-type="pmid">30554520</pub-id><pub-id pub-id-type="doi">10.1164/rccm.201712-2410OC</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seibold</surname><given-names>MA</given-names></name><etal/></person-group><article-title>The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium</article-title><source>PloS one</source><year>2013</year><volume>8</volume><elocation-id>e58658</elocation-id><pub-id pub-id-type="pmcid">PMC3603941</pub-id><pub-id pub-id-type="pmid">23527003</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0058658</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plantier</surname><given-names>L</given-names></name><etal/></person-group><article-title>Ectopic respiratory epithelial cell differentiation in bronchiolised distal airspaces in idiopathic pulmonary fibrosis</article-title><source>Thorax</source><year>2011</year><volume>66</volume><fpage>651</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">21422041</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rock</surname><given-names>JR</given-names></name><name><surname>Randell</surname><given-names>SH</given-names></name><name><surname>Hogan</surname><given-names>BL</given-names></name></person-group><article-title>Airway basal stem cells: a perspective on their roles in epithelial homeostasis and remodeling</article-title><source>Dis Model Mech</source><year>2010</year><volume>3</volume><fpage>545</fpage><lpage>556</lpage><pub-id pub-id-type="pmcid">PMC2931533</pub-id><pub-id pub-id-type="pmid">20699479</pub-id><pub-id pub-id-type="doi">10.1242/dmm.006031</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smirnova</surname><given-names>NF</given-names></name><etal/></person-group><article-title>Detection and quantification of epithelial progenitor cell populations in human healthy and IPF lungs</article-title><source>Respiratory research</source><year>2016</year><volume>17</volume><fpage>83</fpage><pub-id pub-id-type="pmcid">PMC4947297</pub-id><pub-id pub-id-type="pmid">27423691</pub-id><pub-id pub-id-type="doi">10.1186/s12931-016-0404-x</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonsdottir</surname><given-names>HR</given-names></name><etal/></person-group><article-title>Basal cells of the human airways acquire mesenchymal traits in idiopathic pulmonary fibrosis and in culture</article-title><source>Lab Invest</source><year>2015</year><volume>95</volume><fpage>1418</fpage><lpage>1428</lpage><pub-id pub-id-type="pmid">26390052</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chilosi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63</article-title><source>Lab Invest</source><year>2002</year><volume>82</volume><fpage>1335</fpage><lpage>1345</lpage><pub-id pub-id-type="pmid">12379768</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasse</surname><given-names>A</given-names></name><etal/></person-group><article-title>BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis</article-title><source>American journal of respiratory and critical care medicine</source><year>2019</year><volume>199</volume><fpage>622</fpage><lpage>630</lpage><pub-id pub-id-type="pmcid">PMC6396865</pub-id><pub-id pub-id-type="pmid">30141961</pub-id><pub-id pub-id-type="doi">10.1164/rccm.201712-2551OC</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kathiriya</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Human alveolar type 2 epithelium transdifferentiates into metaplastic KRT5+ basal cells</article-title><source>Nature Cell Biology</source><year>2022</year><volume>24</volume><fpage>10</fpage><lpage>23</lpage><pub-id pub-id-type="pmcid">PMC8761168</pub-id><pub-id pub-id-type="pmid">34969962</pub-id><pub-id pub-id-type="doi">10.1038/s41556-021-00809-4</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaughan</surname><given-names>AE</given-names></name><etal/></person-group><article-title>Lineage-negative progenitors mobilize to regenerate lung epithelium after major injury</article-title><source>Nature</source><year>2015</year><volume>517</volume><fpage>621</fpage><lpage>625</lpage><pub-id pub-id-type="pmcid">PMC4312207</pub-id><pub-id pub-id-type="pmid">25533958</pub-id><pub-id pub-id-type="doi">10.1038/nature14112</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Extracellular matrix in lung development, homeostasis and disease</article-title><source>Matrix Biol</source><year>2018</year><volume>73</volume><fpage>77</fpage><lpage>104</lpage><pub-id pub-id-type="pmcid">PMC6129220</pub-id><pub-id pub-id-type="pmid">29524630</pub-id><pub-id pub-id-type="doi">10.1016/j.matbio.2018.03.005</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hynes</surname><given-names>RO</given-names></name><name><surname>Naba</surname><given-names>A</given-names></name></person-group><article-title>Overview of the matrisome--an inventory of extracellular matrix constituents and functions</article-title><source>Cold Spring Harb Perspect Biol</source><year>2012</year><volume>4</volume><elocation-id>a004903</elocation-id><pub-id pub-id-type="pmcid">PMC3249625</pub-id><pub-id pub-id-type="pmid">21937732</pub-id><pub-id pub-id-type="doi">10.1101/cshperspect.a004903</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnans</surname><given-names>C</given-names></name><name><surname>Chou</surname><given-names>J</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>Remodelling the extracellular matrix in development and disease</article-title><source>Nat Rev Mol Cell Biol</source><year>2014</year><volume>15</volume><fpage>786</fpage><lpage>801</lpage><pub-id pub-id-type="pmcid">PMC4316204</pub-id><pub-id pub-id-type="pmid">25415508</pub-id><pub-id pub-id-type="doi">10.1038/nrm3904</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsukui</surname><given-names>T</given-names></name><etal/></person-group><article-title>Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis</article-title><source>Nature communications</source><year>2020</year><volume>11</volume><elocation-id>1920</elocation-id><pub-id pub-id-type="pmcid">PMC7174390</pub-id><pub-id pub-id-type="pmid">32317643</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-15647-5</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>J</given-names></name><name><surname>Henke</surname><given-names>CA</given-names></name><name><surname>Bitterman</surname><given-names>PB</given-names></name></person-group><article-title>Extracellular matrix as a driver of progressive fibrosis</article-title><source>J Clin Invest</source><year>2018</year><volume>128</volume><fpage>45</fpage><lpage>53</lpage><pub-id pub-id-type="pmcid">PMC5749528</pub-id><pub-id pub-id-type="pmid">29293088</pub-id><pub-id pub-id-type="doi">10.1172/JCI93557</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><etal/></person-group><article-title>Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2015</year><volume>308</volume><fpage>L344</fpage><lpage>357</lpage><pub-id pub-id-type="pmcid">PMC4329470</pub-id><pub-id pub-id-type="pmid">25502501</pub-id><pub-id pub-id-type="doi">10.1152/ajplung.00300.2014</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><etal/></person-group><article-title>Mechanosensing by the α6-integrin confers an invasive fibroblast phenotype and mediates lung fibrosis</article-title><source>Nature Communications</source><year>2016</year><volume>7</volume><elocation-id>12564</elocation-id><pub-id pub-id-type="pmcid">PMC4992155</pub-id><pub-id pub-id-type="pmid">27535718</pub-id><pub-id pub-id-type="doi">10.1038/ncomms12564</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamouille</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Derynck</surname><given-names>R</given-names></name></person-group><article-title>Molecular mechanisms of epithelial-mesenchymal transition</article-title><source>Nat Rev Mol Cell Biol</source><year>2014</year><volume>15</volume><fpage>178</fpage><lpage>196</lpage><pub-id pub-id-type="pmcid">PMC4240281</pub-id><pub-id pub-id-type="pmid">24556840</pub-id><pub-id pub-id-type="doi">10.1038/nrm3758</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puttur</surname><given-names>F</given-names></name><etal/></person-group><article-title>Pulmonary environmental cues drive group 2 innate lymphoid cell dynamics in mice and humans</article-title><source>Sci Immunol</source><year>2019</year><volume>4</volume><pub-id pub-id-type="pmcid">PMC6744282</pub-id><pub-id pub-id-type="pmid">31175176</pub-id><pub-id pub-id-type="doi">10.1126/sciimmunol.aav7638</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>KM</given-names></name><name><surname>Sixt</surname><given-names>M</given-names></name></person-group><article-title>Mechanisms of 3D cell migration</article-title><source>Nat Rev Mol Cell Biol</source><year>2019</year><volume>20</volume><fpage>738</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">31582855</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostaço-Guidolin</surname><given-names>LB</given-names></name><etal/></person-group><article-title>Collagen morphology and texture analysis: from statistics to classification</article-title><source>Sci Rep</source><year>2013</year><volume>3</volume><elocation-id>2190</elocation-id><pub-id pub-id-type="pmcid">PMC3709165</pub-id><pub-id pub-id-type="pmid">23846580</pub-id><pub-id pub-id-type="doi">10.1038/srep02190</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Nadiarynkh</surname><given-names>O</given-names></name><name><surname>Plotnikov</surname><given-names>S</given-names></name><name><surname>Campagnola</surname><given-names>PJ</given-names></name></person-group><article-title>Second harmonic generation microscopy for quantitative analysis of collagen fibrillar structure</article-title><source>Nat Protoc</source><year>2012</year><volume>7</volume><fpage>654</fpage><lpage>669</lpage><pub-id pub-id-type="pmcid">PMC4337962</pub-id><pub-id pub-id-type="pmid">22402635</pub-id><pub-id pub-id-type="doi">10.1038/nprot.2012.009</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mostaço-Guidolin</surname><given-names>LB</given-names></name><etal/></person-group><article-title>Defective Fibrillar Collagen Organization by Fibroblasts Contributes to Airway Remodeling in Asthma</article-title><source>American journal of respiratory and critical care medicine</source><year>2019</year><volume>200</volume><fpage>431</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">30950644</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrera</surname><given-names>J</given-names></name><etal/></person-group><article-title>Registration of the extracellular matrix components constituting the fibroblastic focus in idiopathic pulmonary fibrosis</article-title><source>JCI insight</source><year>2019</year><volume>4</volume><pub-id pub-id-type="pmcid">PMC6485370</pub-id><pub-id pub-id-type="pmid">30626754</pub-id><pub-id pub-id-type="doi">10.1172/jci.insight.125185</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barkauskas</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Type 2 alveolar cells are stem cells in adult lung</article-title><source>J Clin Invest</source><year>2013</year><volume>123</volume><fpage>3025</fpage><lpage>3036</lpage><pub-id pub-id-type="pmcid">PMC3696553</pub-id><pub-id pub-id-type="pmid">23921127</pub-id><pub-id pub-id-type="doi">10.1172/JCI68782</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Helvert</surname><given-names>S</given-names></name><name><surname>Storm</surname><given-names>C</given-names></name><name><surname>Friedl</surname><given-names>P</given-names></name></person-group><article-title>Mechanoreciprocity in cell migration</article-title><source>Nat Cell Biol</source><year>2018</year><volume>20</volume><fpage>8</fpage><lpage>20</lpage><pub-id pub-id-type="pmcid">PMC5943039</pub-id><pub-id pub-id-type="pmid">29269951</pub-id><pub-id pub-id-type="doi">10.1038/s41556-017-0012-0</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaukonen</surname><given-names>R</given-names></name><name><surname>Jacquemet</surname><given-names>G</given-names></name><name><surname>Hamidi</surname><given-names>H</given-names></name><name><surname>Ivaska</surname><given-names>J</given-names></name></person-group><article-title>Cell-derived matrices for studying cell proliferation and directional migration in a complex 3D microenvironment</article-title><source>Nat Protoc</source><year>2017</year><volume>12</volume><fpage>2376</fpage><lpage>2390</lpage><pub-id pub-id-type="pmid">29048422</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaukonen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription</article-title><source>Nature communications</source><year>2016</year><volume>7</volume><elocation-id>12237</elocation-id><pub-id pub-id-type="pmcid">PMC4976218</pub-id><pub-id pub-id-type="pmid">27488962</pub-id><pub-id pub-id-type="doi">10.1038/ncomms12237</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgstaller</surname><given-names>G</given-names></name><etal/></person-group><article-title>The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease</article-title><source>The European respiratory journal</source><year>2017</year><volume>50</volume><pub-id pub-id-type="pmid">28679607</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Åhrman</surname><given-names>E</given-names></name><etal/></person-group><article-title>Quantitative proteomic characterization of the lung extracellular matrix in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis</article-title><source>J Proteomics</source><year>2018</year><volume>189</volume><fpage>23</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">29501846</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duerr</surname><given-names>J</given-names></name><etal/></person-group><article-title>Conditional deletion of Nedd4-2 in lung epithelial cells causes progressive pulmonary fibrosis in adult mice</article-title><source>Nature communications</source><year>2020</year><volume>11</volume><elocation-id>2012</elocation-id><pub-id pub-id-type="pmcid">PMC7181726</pub-id><pub-id pub-id-type="pmid">32332792</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-15743-6</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Quantitative proteomic characterization of lung tissue in idiopathic pulmonary fibrosis</article-title><source>Clin Proteomics</source><year>2019</year><volume>16</volume><fpage>6</fpage><pub-id pub-id-type="pmcid">PMC6364390</pub-id><pub-id pub-id-type="pmid">30774578</pub-id><pub-id pub-id-type="doi">10.1186/s12014-019-9226-4</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lennon</surname><given-names>R</given-names></name><etal/></person-group><article-title>Global analysis reveals the complexity of the human glomerular extracellular matrix</article-title><source>J Am Soc Nephrol</source><year>2014</year><volume>25</volume><fpage>939</fpage><lpage>951</lpage><pub-id pub-id-type="pmcid">PMC4005295</pub-id><pub-id pub-id-type="pmid">24436468</pub-id><pub-id pub-id-type="doi">10.1681/ASN.2013030233</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naba</surname><given-names>A</given-names></name><etal/></person-group><article-title>The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices</article-title><source>Mol Cell Proteomics</source><year>2012</year><volume>11</volume><elocation-id>M111.014647</elocation-id><pub-id pub-id-type="pmcid">PMC3322572</pub-id><pub-id pub-id-type="pmid">22159717</pub-id><pub-id pub-id-type="doi">10.1074/mcp.M111.014647</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang da</surname><given-names>W</given-names></name><name><surname>Sherman</surname><given-names>BT</given-names></name><name><surname>Lempicki</surname><given-names>RA</given-names></name></person-group><article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title><source>Nat Protoc</source><year>2009</year><volume>4</volume><fpage>44</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">19131956</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sureshbabu</surname><given-names>A</given-names></name><etal/></person-group><article-title>IGFBP5 induces cell adhesion, increases cell survival and inhibits cell migration in MCF-7 human breast cancer cells</article-title><source>J Cell Sci</source><year>2012</year><volume>125</volume><fpage>1693</fpage><lpage>1705</lpage><pub-id pub-id-type="pmid">22328518</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>C</given-names></name><name><surname>Mason</surname><given-names>RJ</given-names></name></person-group><article-title>Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis</article-title><source>The American journal of pathology</source><year>1995</year><volume>147</volume><fpage>1759</fpage><lpage>1769</lpage><pub-id pub-id-type="pmcid">PMC1869942</pub-id><pub-id pub-id-type="pmid">7495300</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hynes</surname><given-names>RO</given-names></name></person-group><article-title>The extracellular matrix: not just pretty fibrils</article-title><source>Science</source><year>2009</year><volume>326</volume><fpage>1216</fpage><lpage>1219</lpage><pub-id pub-id-type="pmcid">PMC3536535</pub-id><pub-id pub-id-type="pmid">19965464</pub-id><pub-id pub-id-type="doi">10.1126/science.1176009</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomos</surname><given-names>IP</given-names></name><etal/></person-group><article-title>Extracellular matrix remodeling in idiopathic pulmonary fibrosis. It is the ‘bed’ that counts and not ‘the sleepers’</article-title><source>Expert Rev Respir Med</source><year>2017</year><volume>11</volume><fpage>299</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">28274188</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Probing ECM remodeling in idiopathic pulmonary fibrosis via second harmonic generation microscopy analysis of macro/supramolecular collagen structure</article-title><source>J Biomed Opt</source><year>2019</year><volume>25</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmcid">PMC7008503</pub-id><pub-id pub-id-type="pmid">31785093</pub-id><pub-id pub-id-type="doi">10.1117/1.JBO.25.1.014505</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tjin</surname><given-names>G</given-names></name><etal/></person-group><article-title>Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis</article-title><source>Dis Model Mech</source><year>2017</year><volume>10</volume><fpage>1301</fpage><lpage>1312</lpage><pub-id pub-id-type="pmcid">PMC5719253</pub-id><pub-id pub-id-type="pmid">29125826</pub-id><pub-id pub-id-type="doi">10.1242/dmm.030114</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilbury</surname><given-names>K</given-names></name><etal/></person-group><article-title>Second harmonic generation microscopy analysis of extracellular matrix changes in human idiopathic pulmonary fibrosis</article-title><source>J Biomed Opt</source><year>2014</year><volume>19</volume><elocation-id>086014</elocation-id><pub-id pub-id-type="pmcid">PMC4137064</pub-id><pub-id pub-id-type="pmid">25134793</pub-id><pub-id pub-id-type="doi">10.1117/1.JBO.19.8.086014</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charras</surname><given-names>G</given-names></name><name><surname>Sahai</surname><given-names>E</given-names></name></person-group><article-title>Physical influences of the extracellular environment on cell migration</article-title><source>Nat Rev Mol Cell Biol</source><year>2014</year><volume>15</volume><fpage>813</fpage><lpage>824</lpage><pub-id pub-id-type="pmid">25355506</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahm</surname><given-names>JM</given-names></name><name><surname>Chevillard</surname><given-names>M</given-names></name><name><surname>Puchelle</surname><given-names>E</given-names></name></person-group><article-title>Wound repair of human surface respiratory epithelium</article-title><source>Am J Respir Cell Mol Biol</source><year>1991</year><volume>5</volume><fpage>242</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">1910810</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilewski</surname><given-names>JM</given-names></name><name><surname>Latoche</surname><given-names>JD</given-names></name><name><surname>Arcasoy</surname><given-names>SM</given-names></name><name><surname>Albelda</surname><given-names>SM</given-names></name></person-group><article-title>Expression of integrin cell adhesion receptors during human airway epithelial repair in vivo</article-title><source>Am J Physiol</source><year>1997</year><volume>273</volume><fpage>L256</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">9252563</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>SR</given-names></name><name><surname>Dorscheid</surname><given-names>DR</given-names></name><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Wojcik</surname><given-names>KR</given-names></name><name><surname>Hamann</surname><given-names>KJ</given-names></name></person-group><article-title>Role of very late adhesion integrins in mediating repair of human airway epithelial cell monolayers after mechanical injury</article-title><source>Am J Respir Cell Mol Biol</source><year>1999</year><volume>20</volume><fpage>787</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">10101012</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hérard</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Fibronectin and its alpha 5 beta 1-integrin receptor are involved in the wound-repair process of airway epithelium</article-title><source>Am J Physiol</source><year>1996</year><volume>271</volume><fpage>L726</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">8944715</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frantz</surname><given-names>C</given-names></name><name><surname>Stewart</surname><given-names>KM</given-names></name><name><surname>Weaver</surname><given-names>VM</given-names></name></person-group><article-title>The extracellular matrix at a glance</article-title><source>J Cell Sci</source><year>2010</year><volume>123</volume><fpage>4195</fpage><lpage>4200</lpage><pub-id pub-id-type="pmcid">PMC2995612</pub-id><pub-id pub-id-type="pmid">21123617</pub-id><pub-id pub-id-type="doi">10.1242/jcs.023820</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlfors</surname><given-names>JE</given-names></name><name><surname>Billiar</surname><given-names>KL</given-names></name></person-group><article-title>Biomechanical and biochemical characteristics of a human fibroblast-produced and remodeled matrix</article-title><source>Biomaterials</source><year>2007</year><volume>28</volume><fpage>2183</fpage><lpage>2191</lpage><pub-id pub-id-type="pmid">17280714</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>JT</given-names></name><name><surname>Horwitz</surname><given-names>AR</given-names></name><name><surname>Schwartz</surname><given-names>MA</given-names></name></person-group><article-title>Cell adhesion: integrating cytoskeletal dynamics and cellular tension</article-title><source>Nat Rev Mol Cell Biol</source><year>2010</year><volume>11</volume><fpage>633</fpage><lpage>643</lpage><pub-id pub-id-type="pmcid">PMC2992881</pub-id><pub-id pub-id-type="pmid">20729930</pub-id><pub-id pub-id-type="doi">10.1038/nrm2957</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cukierman</surname><given-names>E</given-names></name><name><surname>Pankov</surname><given-names>R</given-names></name><name><surname>Stevens</surname><given-names>DR</given-names></name><name><surname>Yamada</surname><given-names>KM</given-names></name></person-group><article-title>Taking cell-matrix adhesions to the third dimension</article-title><source>Science</source><year>2001</year><volume>294</volume><fpage>1708</fpage><lpage>1712</lpage><pub-id pub-id-type="pmid">11721053</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doyle</surname><given-names>AD</given-names></name><name><surname>Carvajal</surname><given-names>N</given-names></name><name><surname>Jin</surname><given-names>A</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>KM</given-names></name></person-group><article-title>Local 3D matrix microenvironment regulates cell migration through spatiotemporal dynamics of contractility-dependent adhesions</article-title><source>Nature communications</source><year>2015</year><volume>6</volume><elocation-id>8720</elocation-id><pub-id pub-id-type="pmcid">PMC4643399</pub-id><pub-id pub-id-type="pmid">26548801</pub-id><pub-id pub-id-type="doi">10.1038/ncomms9720</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation</article-title><source>American journal of respiratory and critical care medicine</source><year>2012</year><volume>186</volume><fpage>866</fpage><lpage>876</lpage><pub-id pub-id-type="pmcid">PMC3530219</pub-id><pub-id pub-id-type="pmid">22936357</pub-id><pub-id pub-id-type="doi">10.1164/rccm.201204-0754OC</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilewski</surname><given-names>JM</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Henry</surname><given-names>AC</given-names></name><name><surname>Knauer</surname><given-names>AV</given-names></name><name><surname>Feghali-Bostwick</surname><given-names>CA</given-names></name></person-group><article-title>Insulin-like growth factor binding proteins 3 and 5 are overexpressed in idiopathic pulmonary fibrosis and contribute to extracellular matrix deposition</article-title><source>The American journal of pathology</source><year>2005</year><volume>166</volume><fpage>399</fpage><lpage>407</lpage><pub-id pub-id-type="pmcid">PMC1602317</pub-id><pub-id pub-id-type="pmid">15681824</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9440(10)62263-8</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>GDF15 is an epithelial-derived biomarker of idiopathic pulmonary fibrosis</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2019</year><volume>317</volume><fpage>L510</fpage><lpage>l521</lpage><pub-id pub-id-type="pmcid">PMC6842909</pub-id><pub-id pub-id-type="pmid">31432710</pub-id><pub-id pub-id-type="doi">10.1152/ajplung.00062.2019</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rydell-Törmänen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Aberrant nonfibrotic parenchyma in idiopathic pulmonary fibrosis is correlated with decreased ß-catenin inhibition and increased Wnt5a/b interaction</article-title><source>Physiol Rep</source><year>2016</year><volume>4</volume><pub-id pub-id-type="pmcid">PMC4823602</pub-id><pub-id pub-id-type="pmid">26997628</pub-id><pub-id pub-id-type="doi">10.14814/phy2.12727</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Espindola</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis</article-title><source>American journal of respiratory and critical care medicine</source><year>2018</year><volume>197</volume><fpage>1443</fpage><lpage>1456</lpage><pub-id pub-id-type="pmcid">PMC6005556</pub-id><pub-id pub-id-type="pmid">29634284</pub-id><pub-id pub-id-type="doi">10.1164/rccm.201707-1519OC</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>W</given-names></name><etal/></person-group><article-title>SPARC suppresses apoptosis of idiopathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>8196</fpage><lpage>8206</lpage><pub-id pub-id-type="pmcid">PMC2832971</pub-id><pub-id pub-id-type="pmid">20061390</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M109.025684</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conforti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis</article-title><source>Cell Death Discov</source><year>2020</year><volume>6</volume><fpage>54</fpage><pub-id pub-id-type="pmcid">PMC7327077</pub-id><pub-id pub-id-type="pmid">32637156</pub-id><pub-id pub-id-type="doi">10.1038/s41420-020-0289-9</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>L</given-names></name><etal/></person-group><article-title>Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis</article-title><source>Cell Death Differ</source><year>2019</year><volume>26</volume><fpage>943</fpage><lpage>957</lpage><pub-id pub-id-type="pmcid">PMC6252080</pub-id><pub-id pub-id-type="pmid">30050057</pub-id><pub-id pub-id-type="doi">10.1038/s41418-018-0175-7</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradshaw</surname><given-names>AD</given-names></name></person-group><article-title>The role of SPARC in extracellular matrix assembly</article-title><source>J Cell Commun Signal</source><year>2009</year><volume>3</volume><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="pmcid">PMC2778582</pub-id><pub-id pub-id-type="pmid">19798598</pub-id><pub-id pub-id-type="doi">10.1007/s12079-009-0062-6</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giudici</surname><given-names>C</given-names></name><etal/></person-group><article-title>Mapping of SPARC/BM-40/osteonectin-binding sites on fibrillar collagens</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><fpage>19551</fpage><lpage>19560</lpage><pub-id pub-id-type="pmcid">PMC2443679</pub-id><pub-id pub-id-type="pmid">18487610</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M710001200</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carraro</surname><given-names>G</given-names></name><etal/></person-group><article-title>Single Cell Reconstruction of Human Basal Cell Diversity in Normal and IPF Lung</article-title><source>American journal of respiratory and critical care medicine</source><year>2020</year><pub-id pub-id-type="pmcid">PMC7706153</pub-id><pub-id pub-id-type="pmid">32692579</pub-id><pub-id pub-id-type="doi">10.1164/rccm.201904-0792OC</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaeger</surname><given-names>B</given-names></name><etal/></person-group><article-title>Airway basal cells show a dedifferentiated KRT17(high)Phenotype and promote fibrosis in idiopathic pulmonary fibrosis</article-title><source>Nature communications</source><year>2022</year><volume>13</volume><elocation-id>5637</elocation-id><pub-id pub-id-type="pmcid">PMC9513076</pub-id><pub-id pub-id-type="pmid">36163190</pub-id><pub-id pub-id-type="doi">10.1038/s41467-022-33193-0</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghu</surname><given-names>G</given-names></name><etal/></person-group><article-title>An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline</article-title><source>American journal of respiratory and critical care medicine</source><year>2015</year><volume>192</volume><fpage>e3</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">26177183</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molyneaux</surname><given-names>PL</given-names></name><etal/></person-group><article-title>Bronchoalveolar Lavage is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study</article-title><source>American journal of respiratory and critical care medicine</source><year>2020</year><pub-id pub-id-type="pmcid">PMC7781115</pub-id><pub-id pub-id-type="pmid">32857629</pub-id><pub-id pub-id-type="doi">10.1164/rccm.202004-1138LE</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><etal/></person-group><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nat Methods</source><year>2012</year><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="pmcid">PMC3855844</pub-id><pub-id pub-id-type="pmid">22743772</pub-id><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCowan</surname><given-names>J</given-names></name><etal/></person-group><article-title>The transcription factor EGR2 is indispensable for tissue-specific imprinting of alveolar macrophages in health and tissue repair</article-title><source>Sci Immunol</source><year>2021</year><volume>6</volume><elocation-id>eabj2132</elocation-id><pub-id pub-id-type="pmcid">PMC7612216</pub-id><pub-id pub-id-type="pmid">34797692</pub-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abj2132</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezakhaniha</surname><given-names>R</given-names></name><etal/></person-group><article-title>Experimental investigation of collagen waviness and orientation in the arterial adventitia using confocal laser scanning microscopy</article-title><source>Biomech Model Mechanobiol</source><year>2012</year><volume>11</volume><fpage>461</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">21744269</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keerthisingam</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Cyclooxygenase-2 deficiency results in a loss of the antiproliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice</article-title><source>The American journal of pathology</source><year>2001</year><volume>158</volume><fpage>1411</fpage><lpage>1422</lpage><pub-id pub-id-type="pmcid">PMC1891895</pub-id><pub-id pub-id-type="pmid">11290559</pub-id><pub-id pub-id-type="doi">10.1016/s0002-9440(10)64092-8</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Chaumont</surname><given-names>F</given-names></name><etal/></person-group><article-title>Icy: an open bioimage informatics platform for extended reproducible research</article-title><source>Nat Methods</source><year>2012</year><volume>9</volume><fpage>690</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">22743774</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Jeong</surname><given-names>Y</given-names></name><name><surname>Jhiang</surname><given-names>SM</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Menq</surname><given-names>CH</given-names></name></person-group><article-title>Quantitative characterization of cell behaviors through cell cycle progression via automated cell tracking</article-title><source>PloS one</source><year>2014</year><volume>9</volume><elocation-id>e98762</elocation-id><pub-id pub-id-type="pmcid">PMC4049640</pub-id><pub-id pub-id-type="pmid">24911281</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0098762</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livak</surname><given-names>KJ</given-names></name><name><surname>Schmittgen</surname><given-names>TD</given-names></name></person-group><article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</article-title><source>Methods</source><year>2001</year><volume>25</volume><fpage>402</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">11846609</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metsalu</surname><given-names>T</given-names></name><name><surname>Vilo</surname><given-names>J</given-names></name></person-group><article-title>ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><fpage>W566</fpage><lpage>570</lpage><pub-id pub-id-type="pmcid">PMC4489295</pub-id><pub-id pub-id-type="pmid">25969447</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkv468</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goedhart</surname><given-names>J</given-names></name><name><surname>Luijsterburg</surname><given-names>MS</given-names></name></person-group><article-title>VolcaNoseR is a web app for creating, exploring, labeling and sharing volcano plots</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><elocation-id>20560</elocation-id><pub-id pub-id-type="pmcid">PMC7689420</pub-id><pub-id pub-id-type="pmid">33239692</pub-id><pub-id pub-id-type="doi">10.1038/s41598-020-76603-3</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Riverol</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences</article-title><source>Nucleic Acids Res</source><year>2022</year><volume>50</volume><fpage>D543</fpage><lpage>d552</lpage><pub-id pub-id-type="pmcid">PMC8728295</pub-id><pub-id pub-id-type="pmid">34723319</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkab1038</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig. 1</label><caption><title>Distinct regional collagen organisation in the fibrotic lung influences KRT5<sup>+</sup> basal cell distribution.</title><p>(a) Schematic of experimental design. Created with BioRender.com. (b) (b, upper) Overview images of IPF distal lung acquired using a Zeiss 880 2-photon microscope with spectral detection and linear unmixing of autofluorescence and second harmonic generation (SHG) signals. Arrows marking single KRT5+ basal cells within matrix. (b, lower panels) Representative images of regions quantitatively analysed; alveolar (ALV), honeycomb cyst (HC), fibrotic (FIBRO), airway (AW), peribronchial (PB) and perivascular (PVS). Red blood cells (RBCs). (c) KRT5+ cells counted per image area (each data point represents the average of 2 – 6 images per area per subject; controls (n = 4) and IPF (n = 8 for PB, PVS, ALV, FIBRO and n = 6 for HC). Data plotted as mean + SEM. (d) Principal component analysis (PCA) of collagen intensity, density, orientation and GLCM parameters. (e-g) Quantitative image analysis per region showing (e) collagen density (f) coherency and (g) entropy. Data plotted as mean + SEM. Each data point represents the average of 2 – 6 images per area per subject; controls (n = 4) and IPF (n = 8 for PB, PVS, ALV, FIBRO and n = 6 for HC). Ordinary one-way ANOVA with Tukey’s multiple comparisons test ****P&lt;0.0001, ***P&lt;0.001, **P&lt;0.01, *p&lt;0.05. (h - i) Correlation analysis between (h) collagen density and KRT5+ cell numbers and (i) collagen orientation/ coherency and KRT5+ numbers in distal lung tissue from IPF patients. Each data point represents the average of 2 – 6 images per area per subject with IPF (n = 8 for PB, PVS, ALV, FIBRO and n = 6 for HC) Linear regression of correlation analysis with best- fit line and 95% confidence bands shown.</p></caption><graphic xlink:href="EMS158911-f001"/></fig><fig id="F2" position="float"><label>Fig. 2</label><caption><title>ECM landscape of normal and fibrotic lung revealed by high-dimensional imaging mass cytometry.</title><p>(a) Imaging mass cytometry (IMC) of distal lung tissue from normal control (n = 1, H&amp;E overview shown) showing distribution of ECM components; collagen I (blue), collagen III (magenta) and versican (green) (left panel), collagen IV (turquoise) (right panel) in relation to KRT5<sup>+</sup> BCs (red). Representative image demonstrating key regions; airway (AW), peribronchial (PB) and alveolar (ALV). (b – d) IMC of distal lung tissue from a patient with IPF (n=1, H&amp;E overview shown) showing distinct regions; (b) peribronchial and perivascular space (PVS), (c) alveolar and fibrotic intersititium (FIBRO), and (d) honeycomb cyst (HC). Upper panel; collagen I (blue), collagen III (magenta) and versican (green). Lower panel; collagen IV (turquoise) and KRT5<sup>+</sup> BCs (red).</p></caption><graphic xlink:href="EMS158911-f002"/></fig><fig id="F3" position="float"><label>Fig. 3</label><caption><title>KRT5<sup>+</sup> cell migration is directly modulated by ECM proteins.</title><p>(a) Flow cytometry confirmed expression of airway BC markers KRT5 and p63 in primary airway epithelial cells in submerged culture (passage 3). (b) Airyscan maximum intensity projection image of KRT5<sup>+</sup> BC from healthy control, demonstrating normal BC morphology and cytoskeletal arrangement on collagen I; F-actin phalloidin stain (green) and DAPI (blue). Scale bar, 10μm. (c) Normal capacity of BCs to undergo mucociliary differentiation shown with H&amp;E (c, upper) and PAS (c, lower) stained sections of agarose embedded air-liquid interface (ALI) cultures. (d) Schematic of cell migration experimental design. Created with BioRender.com. (e) Individual cell track trajectories from all healthy (e, upper panels) and IPF (e, lower panels) donors plotted according to ECM substrate. Scale bars, 100μm. (f – h) Beeswarm SuperPlot showing (f) track speed, (g) straightness ratio, and (h) displacement over 12-hours, for KRT5+ cells from healthy controls (n = 5) and patients with IPF (n = 5) cultured on collagen I (grey), collagen III (magenta), collagen IV (green) and versican (purple). Each small dot (healthy) or square (IPF) represents cell-level data which is colour coded according to biological replicate. The larger circles (healthy) and squares (IPF) represent the mean value per biological replicate. Summary statistics with mean and standard deviation are superimposed on the plot. Sample-level means compared using a one-way ANOVA with Tukey’s multiple comparison test, ****p&lt;0.0001, **p&lt;0.01, *p&lt;0.05. (i) Mean square displacement of all tracks per substrate.</p></caption><graphic xlink:href="EMS158911-f003"/></fig><fig id="F4" position="float"><label>Fig. 4</label><caption><title>Interaction with a 3D cell-derived matrix induces gene expression changes in migratory KRT5<sup>+</sup> cells.</title><p>(a) Schematic of experimental design for KRT5+ cell migration on CDM. Created with BioRender.com. (b) Imaging showing generation of CDM from primary HLFs pre- (b, upper) and post- (b, lower) decellularization; F-actin (phalloidin, green), DAPI (blue), collagen I (red) and fibronectin (purple). (c – e) Beeswarm SuperPlot showing (c) track speed, (d) straightness ratio, and (e) displacement over 12-hours, for KRT5+ cells from healthy controls (n=4) and IPF patients (n=4) tracked through IPF HLF CDM. Each small dot represents cell-level data which is colour coded according to biological replicate. The larger circles represent the mean value per biological replicate. Summary statistics with mean and standard deviation are superimposed on the plot. Sample-level means compared using a one-way ANOVA with Tukey’s multiple comparison test. (f) Mean square displacement of all healthy KRT5+ cells (black) vs. IPF KRT5+ cells (red) on IPF CDMs (g) Individual cell tracks from healthy (black) or IPF (red) KRT5+ cells plotted from centroid; Scale bar, 100μm. (h) Schematic of experimental design to assess KRT5+ cell gene expression changes induced by culture on collagen I (2D) versus IPF CDM (3D). (i) Principal component analysis of gene array data; unit variance scaling was applied to rows; SVD with imputation was used to calculate principal components. Prediction ellipses are such that with probability 0.95, a new observation from the same group will fall inside the ellipse. (j) Hierarchical clustering of normalised gene expression. Rows and columns using correlation distance and average linkage. Rows are centred and unit variance scaling is applied. (k) Volcano plots showing gene expression changes when healthy (left) or IPF (right) KRT5+ cells were cultured on IPF CDM vs. collagen I. Upregulated genes (red), downregulated genes (blue). Significance defined as log fold change &gt;2 or &lt;2, p&lt;0.05. P values were calculated based on a Student's t-test of the replicate normalised gene expression values (2^(-Delta CT)) for each gene in control and test groups. Housekeeping genes used - ACTB, B2M and RPLP0.</p></caption><graphic xlink:href="EMS158911-f004"/></fig><fig id="F5" position="float"><label>Fig. 5</label><caption><title>IPF fibroblast-derived matrix restrains basal cell migration.</title><p>(a) Schematic of experimental design for KRT5+ cell migration on CDM from control or IPF HLFs. Created with BioRender.com. (b) Imaging showing KRT5+ cell interacting with fibronectin fibres; KRT5 (yellow), DAPI (turquoise) and fibronectin (purple). (c – e) Beeswarm SuperPlot showing (c) track speed, (d) straightness ratio, and (e) displacement over 12-hours, of KRT5+ cells from healthy controls tracked through CDMs from control (n=3) or IPF HLFs (n=3). Each small dot represents cell-level data which is colour coded according to biological replicate. The larger circles represent the mean value per biological replicate. Summary statistics with mean and standard deviation are superimposed on the plot. Sample-level means compared using a one-way ANOVA with Tukey’s multiple comparison test. (f- g) Individual cell tracks from all healthy KRT5+ cells on control CDMs (black) or IPF CDMs (red) plotted from (f) centroid and (g) actual trajectories; Scale bar, 100μm. (h) Histogram showing frequency distribution (%) of cell tracks by displacement on control CDMs (black) compared to IPF CDMs (red). Non-migratory cells with displacement &lt;20μm were excluded. Histogram bin width = 20μm, centre of first bin = 30μm. (i) Mean square displacement of all healthy KRT5+ cells on control (black) on IPF (red) CDMs.</p></caption><graphic xlink:href="EMS158911-f005"/></fig><fig id="F6" position="float"><label>Fig. 6</label><caption><title>IPF fibroblast-derived matrix has a distinct matrisome.</title><p>(a) Schematic of experimental design for MS-proteomics of CDMs from control (n=3 in duplicate) and IPF (n=3 in duplicate) HLFs. Created with BioRender.com. (b) GO Biological Pathways using DAVID v6.8 functional annotation tool for 154 matrisome proteins identified in CDMs (Benjamini-Hochberg adjusted p-value). (c) Radar plot of protein abundance according to matrisome categories identified in control (black) and IPF (red) CDMs. (d) PCA of 154 matrisome proteins identified in control and IPF CDMs. Unit variance scaling is applied to rows; SVD with imputation is used to calculate principal components. Prediction ellipses are such that with probability 0.95, a new observation from the same group will fall inside the ellipse. (e) hierarchical clustering of normalised abundance of each protein identified. Rows and columns using correlation distance and average linkage. Rows are centred and unit variance scaling is applied. (f) Volcano plot showing significant differentially expressed proteins between IPF CDMs and control CDMs, upregulated proteins (red), downregulated proteins (blue). Significance defined as a fold change &gt;2 or &lt;2, p&lt;0.05. (g) Venn diagram showing shared GO biological processes for significantly differentially expressed proteins. (h) Protein-protein interaction network using STRING v11 using matrisome proteins with an abundance ratio &gt;2 or &lt;2, p&lt;0.05.</p></caption><graphic xlink:href="EMS158911-f006"/></fig><fig id="F7" position="float"><label>Fig. 7</label><caption><title>SPARC restricts KRT5+ cell migration.</title><p>(a – c) Beeswarm SuperPlot showing (a) track speed, (b) straightness ratio, and (c) displacement over 12-hours, for KRT5+ cells from healthy controls (n=6) cultured in tissue culture wells with no coating (magenta), collagen I alone (blue) or collagen I with SPARC 20μg/ml (green). Each small dot represents cell-level data which is colour coded according to biological replicate. The larger circles represent the mean value per biological replicate. Summary statistics with mean and standard deviation are superimposed on the plot. Sample-level means compared using a one-way ANOVA with Tukey’s multiple comparison test, ****p&lt;0.0001, **p&lt;0.01, *p&lt;0.05. (d – e) All tracks from healthy KRT5+ cells on collagen I (blue) or collagen I and SPARC (green) plotted as (d) actual trajectories and (e) from centroid; Scale bar, 100μm. (f) Mean square displacement of all healthy KRT5+ cells on collagen I (blue) or collagen I and SPARC (green). (g) Graphical abstract showing KRT5+ cells retained within SPARC-rich CDM produced by IPF HLFs, leading to tissue pathology. Created with BioRender.com.</p></caption><graphic xlink:href="EMS158911-f007"/></fig></floats-group></article>